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palavras-chave  Exossoma, métodos de isolação de exosomas, Doença de Alzheimer, sAPPα, sAPPβ, biomarcador 
resumo   
Os exossomas são pequenas vesículas extracelulares envolvidas em vários processos fisiológicos e patológicos. O potencial dos exosomas como fontes de biomarcadores para o diagnóstico, prognóstico e mesmo para a terapêutica tem intensificado a investigação nesta área, apoiando o potencial dos exosomas na descoberta de biomarcadores. A centrifugação diferencial é o método mais usado, mas é demorado, requer grandes volumes de amostra e as altas velocidades de centrifugação podem comprometer a integridade dos exossomas. Apesar das várias opções disponíveis, nenhum consenso foi atingido quanto à melhor metodologia para isolar exossomas.  Neste estudo, dois métodos baseados em precipitação e um método baseado em colunas foram comparados para a isolação de exosomas a partir de soro, plasma e líquido cefalorraquidiano humano (LCR). Foi realizada uma completa caracterização dos exosomas isolados, incluindo a análise do tamanho e estabilidade das partículas, análise da morfologia por microscopia eletrónica de transmissão, incluindo métodos de quantificação de partículas e proteína. Todos os métodos isolaram exosomas a partir dos três biofluidos, contudo apresentaram performances diferentes em termos de rendimento exossomal. Estes dados apoiam a hipótese de que para além da ultracentrifugação outros métodos podem ser aplicados para isolar exosomas no contexto da investigação clínica e translacional. Neste estudo foi também explorado o potencial dos exosomas derivados do soro humano como transportadores de biomarcadores candidatos para a Doença de Alzheimer (DA). Estes podem representar métodos menos invasivos do que o atual diagnóstico neuroquímico para a DA, baseado no LCR. Neste caso, foi monitorizado o potencial de sAPPα e sAPPβ nos exosomas extraídos de soro de indivíduos com demência moderada, severa e casos de DA diagnosticados. Foi observada uma diminuição nas médias de sAPPα e sAPPβ dos exosomas neuronais derivados do soro, suportando o potencial dos exosomas na descoberta de biomarcadores para a DA.  
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abstract  Exosomes are small extracellular vesicles involved in various physiological and pathological processes. The potential of exosomes as biomarker resources for diagnostics, prognostics and even for therapeutics has intensified research in the field supporting the potential of exosomes in AD biomarker discovery.  Differential centrifugation is the most used method but is time-consuming, requires larger volumes of sample, and the high centrifuge speed compromise exosome integrity. Despite the various approaches available, no consensus on which is the best methodology to isolate exosomes have been reached thus far. Thus, in this study, two precipitation-based methods and one column-based method were compared for exosome isolation from human serum, plasma and cerebrospinal fluid. A complete exosome characterization was carried out, including size and particle stability analysis, morphological assessment by transmission electron microscopy and yield quantification methods. All methods isolated exosomes from the three biofluids although in terms of exosome yield they performed differently. These data support the notion that other methods than ultracentrifugation can be successfully applied to isolate exosomes, that can be further used in the context of translational and clinical research.  It was also explored the value of serum-derived exosomes as carriers of candidate Alzheimer’s disease (AD) biomarkers. These may represent less invasive approaches than CSF-based neurodegenerative diagnostic currently used for AD. In this case, the potential of serum-derived exosome sAPPα and sAPPβ was monitored, in cognitive demented individuals including AD diagnosed cases. A decrease in sAPPα and sAPPβ levels of serum-derived neuronal exosomes was obtained in individuals with moderate, severe dementia and AD confirmed from respective controls, supporting the potential of exosome in AD biomarker discovery.              
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1. Exosomes overview 
Cellular communication is essential to life and can be mediated by direct cell contact or 
through molecule secretion. In the 1980s, another mechanism for cell communication that 
involves the release of membrane vesicles (nanovesicles) into the extracellular space and 
consequent influence on target cells has emerged. These nanovesicles are formed by vesiculation 
inside an intracellular endosome, forming a multivesicular body (MVB). MVBs have the capacity to 
fuse with plasma membrane (PM) and release vesicles into the extracellular space [1, 2]. In 1987, 
the term “exosome” was adopted for these small vesicles (30-150 nm) of endosomal origin [3].  
 
1.1. Exosome biogenesis  
 As mentioned, exosomes are originated from intraluminal vesicles (ILVs) of MVBs. These 
vesicles or early endosomes are formed by inward budding of PM with internalization of selected 
cargo. Early endosomes mature into late endosomes or MVBs that accumulate various 
endosomes inside their lumen [4]. Different subpopulations of MVBs can fuse with plasma 
membrane, resulting in exosome secretion, or fuse with lysosomes to destroy their content 
(Figure 1).  
 
 Figure 1. Mechanisms of exosome biogenesis. Plasma membrane budding inward result in early endosomes that mature in late endosomes or MVBs. MBVs can then fuse with plasma membrane resulting in exosome secretion or fuse with lysosome for degradation. MVBs: Multivesicular bodies. TGN: Trans-Golgi network. 
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Neither MVBs content sorting or MVBs destiny is aleatory, being those processes 
controlled in part by lipid metabolism and lipid composition at PM. For example, 
phosphatidylinositol 3-phosphate (PI3P) is present in early endosomes [5] and plays an important 
role in protein targeting. FYVE protein domains of Endosomal Sorting Complex Required for 
Transport (ESCRT)-0, involved in exosome biogenesis, directly bind to PI3P (reviewed in [6]). In 
addition, PI3P contributes for regulation of membrane dynamics and endosome mobility by 
recruiting kinesins [7]. Protein-to-protein interactions can also regulate the selection of protein 
cargo of ILVs, as chaperone heat shock protein 70 (Hsp70) that binds not only to endosomal acidic 
phospholipids but also to cytosolic proteins, conferring selectively in inclusion of proteins into ILVs 
[8].  
 Different cell types secrete different subpopulations of exosomes with distinct cargo and 
consequently different mechanisms for exosome biogenesis may be involved. Endosomal Sorting 
Complex Required for Transport is the most common studied mechanism involved in MVBs 
formation. It is composed by four complexes and approximately thirty proteins [9]. ESCRT-0 
complex binds to transmembrane proteins that are ubiquitinated and thus destined for 
degradation. This interaction occurs via hepatocyte growth factor – regulated tyrosine kinase 
substrate (HRS) which recognizes ubiquitin. Signal transducing adaptor molecule (STAM) is 
another ESCRT-0 component that interacts directly with HRS. In turn, HRS can recruit the Tumour 
susceptibility gene 101 protein (TSG101) that is a member of ESCRT-I. Consequently, ESCRT-I 
recruits ESCRT-II and finally ESCRT-III via ESCRT-II. Various studies support the role of HRS in 
ESCRT-I recruitment as HRS inhibition resulted in decreased exosome secretion, in different cell 
lines [10–13]. Moreover, silencing of ESCRT-0 component STAM gene, ESCRT-I TSG101 gene or 
depletion of Programmed cell death 6-interacting protein (ALIX), the later involved in ESCRT-III 
recruitment, result in decreased exosome secretion [12].  
 ESCRT-I and ESCRT-II are both tetramers involved in budding formation, sequester of 
ubiquitinated proteins and seem to be essential for exosome secretion. Their structure helps to 
stabilize the bud upon interaction. Inhibition of charge multivesicular body protein 4 (CHMP4) 
isoforms (ESCRT-III component) in MCF-7 cell line resulted in decreased exosome secretion 
containing syndecan, CD63 and syntenin [14]. Lastly, ESCRT-III complex is involved in scission of 
ILV, dissociation and recycling of ESCRT is dependent of the AAA-ATPase Vacuolar protein sorting 
4 (VPS4) activity, suggesting that ESCRT-III polymers disassembly requires ATP hydrolysis [15]. 
However, VPS can interact with ESCRT-III also independently of ATP hydrolysis as shown in 
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deficient VPS24 -VPS2 protein chimeras [16]. The role of VPS4 in ILV formation is still unclear: 
inhibition of VPS4B in HeLa-CIITA cells increased exosome secretion [12] but concomitant 
depletion of VPS4A and VPS4B in MCF-7 cells decreased exosome secretion [14]. Thus, exosome 
secretion can be also dependent of ESCRT-III complex [14]. 
Exosome biogenesis can occur also in a ESCRT independent manner, as initially shown in 
oligodendroglial cell line when ALIX and TSG101 were depleted [17] and in human HEp-2 cells 
facing depletion of ESCRT complexes [18]. Lipids, tetraspanins and heat shock proteins seems to 
be the essential elements involved in ESCRT independent mechanisms that probably occur 
concomitantly with ESCRT mechanisms.  
Some lipids are also essential to exosome biogenesis as ceramide and sphingomyelin. 
Inhibition of neutral sphingomyelinases (nSMase), enzymes responsible for hydrolysis of 
sphingomyelin to ceramide, results in decreased exosome secretion, carrying the proteolipid 
protein (PLP), in an oligodendroglial cell line. Further, ESCRT machinery depletion still results in 
exosomes secretion with PLP suggesting that exosome biogenesis can be independent of ESCRT 
mechanisms and ceramide is crucial element [17]. In addition, induction of cholesterol 
accumulation results in increased levels of exosomes carrying mainly flotillin which suggests that 
exosomes and flotillin can be involved in cholesterol homeostasis regulation [19]. 
Tetraspanins can also be involved in exosome biogenesis by ESCRT independent 
mechanisms. CD63 was the first tetraspanin found to be involved in exosome biogenesis and 
secretion [20]. CD81 is another tetraspanin involved in selection of exosome cargo proteins, 
through interaction with specific ligands [21]. CD9 and CD82 when overexpressed in HEK293 cells 
increased exosome secretion of β-Catenin, although in a ceramide dependent process, suggesting 
that β-Catenin secretion into exosomes is associated to Wnt signalling pathway downregulation 
(for example, involved in cell proliferation) [22]. In addition, the expression of tetraspanin Tspan8 
modified exosome protein content, mRNA and miRNA cargo with effects into tumour 
angiogenesis in rat pancreatic adenocarcinoma cells [23].  
Considering all current knowledge about exosome biogenesis it seems likely different 
subpopulations of MVBs as well as different mechanisms involved in exosome biogenesis in a cell 
could exist.  
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1.2. Exosomes secretion machinery 
MVBs fuse with plasma membrane leading to the secretion of exosomes. In this process, 
several small GTPases from RAB family are involved, depending on cell type (Figure 2). The first 
Ras-related protein (RAB) involved in exosome secretion identified was RAB11 [24]. Inhibition of 
RAB11 lead to reduction of exosome secretion bearing the transferrin receptor [24] and is crucial 
to MVBs docking with PM in an intracellular calcium rising-dependent mechanism [25]. RAB35 is 
also crucial for exosome secretion since its inhibition decreased exosome secretion in murine 
oligodendroglial cell line [26] and in primary oligodendrocytes [27]. Silencing of RAB2B, RAB5SA, 
RAB9A, RAB27A and RAB27B through small hairpin RNA also results in decreased exosome 
secretion in HeLa-CIITA cells [28]. These effects were more significant for RAB27A and RAB27B 
depletion, suggesting that these RABs could be involved in MVBs fusion with PM [28]. In contrast, 
RAB7 was essential for exosome secretion in MCF-7 cells [14] and RAB11 in Drosophila S2 cells 
[29]. RAB 11 and RAB35 depletion in RPE1 cells led to decreased exosomes secretion. Dual effects 
have been described for RAB27A/B (associated with late endosome and secretory compartments), 
silencing of RAB27A/B did not influence secretion rates [30] but depletion of RAB27A is correlated 
with less exosome secretion in various cells lines [13, 31–33]. Concomitant depletion of RAB27A 
and RAB27B in myofibroblasts cells rendered in decreased exosome secretion [33] as shRNA 
RAB27A/B inhibition in human breast cancer MDA-MB-231 [34].  
The fusion of MVBs with PM and consequently exosome secretion is not completely 
understood. Soluble NSF-attachment protein receptors (SNARE) are known to be involved in 
fusion of lipid membranes however SNAREs effects on exosome secretion are controversial. 
Inhibition of SNARE protein VAMP7 in canine MDCK cells did not impair the secretion of exosomes 
[35]. However, exosome secretion in HEK293 cells containing Wnt was found to be dependent of 
the R-SNARE protein Ykt6 [11] which is present in the MVBs [36]. Hence, controversial results may 
be explained by involvement of different SNARE complexes in the secretion of different exosome 
subpopulations. 
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There are also several molecules involved in exosome secretion beyond SNARE proteins, 
although it is not well clear whether their role is related to ILVs biogenesis in MVBs or with 
exosome secretion. Diacyl glycerol kinase α (DGKα) is one of those molecules. T cells inhibitions 
by DGKα decreased exosome secretion bearing Fas ligand [37] and regulated the polarised 
secretion of exosomes [38]. Using the nematode Caenorhabditis elegans, the V0 complex of the 
H+- vacuolar ATPase was found to promote exosome secretion and recently it was found that the 
GTPase RAL-1 regulates MVB formation and exosome secretion [39]. 
Figure 2. Machinery of exosome secretion. Outward budding for exosome secretion is regulated by endosomal sorting complex required for transport complex (ESCRT) components and many Ras-related proteins in the brain (RABs). SNARE: soluble NSF attachment receptor. MVBs: Multivesicular bodies. TGN: Trans-Golgi network. SNARE: Soluble NSF-attachment protein receptors. 
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1.3.    Exosome composition 
 Exosomes composition is very similar to endosomes and, in a less closer manner, similar 
to the composition of plasma membrane and cytosol (Figure 3) [40]. The study of protein content 
of exosomes, isolated from cell cultures and body fluids has been based in antibody detection 
techniques as western blotting, protein staining or proteomic analysis as mass spectrometry.  
However, there is still a large number of proteins and nucleic acids secreted into exosomes to be 
identified. Exosomes are specially enriched in proteins derived of the plasma membrane, 
endosomal compartment or cytosol and in some lipids as phosphatidylethanolamide [41], 
ceramide [17], cholesterol [42, 43] and saturated fatty acids [44] but it can also include nucleic 
acids. Indeed, since it was discovered that exosomes carry various species of mRNA [45], miRNA 
[45] and small non-coding RNAs [46], exosome genetic cargo under physiological and pathological 
conditions have been the focus of intensive research. Moreover, the sorting of miRNA into 
exosomes is not aleatory and seems to be regulated by a motif of 4 nucleotides (GGAG). This 
motif is recognized by sumoylated nuclear ribonucleoprotein A2B that loads miRNA into 
exosomes of human embryonic kidney cells 293 [47]. Moreover, in macrophages miRNA cargo 
into exosomes was shown to be also regulated by the levels of target mRNA [48]. 
 
 
 
 
 
 
 
 
 
 Figure 3. Exosomes general composition. Exosomes are composed by various protein, lipids and nucleic acids. Among those are adhesion molecules as tetraspanins and integrins; antigen presentation as MHC class I and MHC class II proteins; signal transduction proteins as G proteins; membrane and fusion proteins as annexins and RABs; cytoskeletal and cytosolic proteins as actin, tubulin and ribosomal proteins; enzymes as glyceraldehyde 3-phosphate dehydrogenase and lipids as ceramide, cholesterol and sphingomyelin. ESCRT: Endosomal sorting complex required for transport; mRNA: Messenger RNA; miRNA: microRNA. 
 9  
1.4.    Exosome isolation methods 
 Exosome isolation from cell culture supernatants or biofluids is a big challenge, especially 
in the last case. Generally, exosome purification techniques are based in exosome characteristics 
as size, density, shape or surface proteins. 
The most common technique for exosome isolation is differential ultracentrifugation 
which includes low speed centrifugation to remove cells and debris (important contaminants of 
exosome suspensions), high speed cycles to remove larger vesicles and then a high 
ultracentrifugation step to pellet exosomes. It consists in a time-consuming method which 
requires expensive material (ultracentrifuge), precipitates protein aggregates and other 
contaminants, resulting in low exosome yields. Further, biofluids viscosity is related to lower 
particle sedimentation so it requires longer ultracentrifugation steps, usually with higher 
centrifugation periods that can comprise the exosome integrity. As an advantage, 
ultracentrifugation does not require sample pre-treatments or any other reagents [49–51].  
Density gradient ultracentrifugation is a variation of ultracentrifugation and is based on 
exosome size, mass and density, efficiently separating exosomes from other vesicles with distinct 
densities. According to this method the sample is placed in the top of a density gradient medium 
(higher densities in the top). Then, it is applied an ultracentrifugation step and various vesicles 
including exosomes move through density gradient medium. Exosomes float until get equilibrium 
density, ranging from 1.08 to 1.22 g/ml on a sucrose gradient, and form a fraction zone that can 
be easily recovered [49–51]. 
The discovery of exosome surface proteins and receptors allowed the development of 
additional methods as immunoaffinity exosome isolation that is based on interactions between 
the antigens, for example highly abundant exosome proteins, and specific antibodies which may 
be coupled to magnetic beads. These magnetic beads can then be analysed by several techniques 
as flow cytometry, electron microscopy, providing higher exosome yields than ultracentrifugation. 
However, exosome immunocapture methods only isolates subpopulations of exosomes, 
depending on exosome marker that was targeted and it is difficult to elute exosomes from beads 
resulting in low exosome yields, requires cell-free suspensions and expensive reagents [49–51].  
The main size-based exosome isolation methods are ultrafiltration and size exclusion 
chromatography (SEC). Ultrafiltration requires a previous centrifugation step to remove cells and 
then fluid suspensions are filtered through membranes in which pores are defined according to 
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exosome size or molecular weight. This is a rapid method however it may co-isolate other 
vesicles, various proteins and lead to vesicles damage due to pressure forces. SEC isolates 
exosomes based on their size, since macromolecules pass thought a porous polymeric phase with 
beads and multiple tunnels and pores. Vesicles with small hydrodynamic diameters ranging from 
30 to 200 nm are trapped into pores and lately eluted. Particles with sizes higher than 1 μm do 
not enter the porous phase and other particles than exosomes enter in the porous zone but are 
not retained. SEC provides purest exosome isolations, preserving exosome integrity but is time-
consuming method [49–51], although less than ultracentrifugation methods. 
Water-excluding polymers isolate exosomes by altering its solubility. This method 
requires a low speed centrifugation step to remove cells and debris, mixing and incubating with 
polymers such as polyethylene glycol that link to water molecules and enhances the precipitation 
of less soluble components as exosomes. Further, the mixture is centrifugated at low speed, 
pelleting exosomes. Polymer-based exosome isolation gives good exosome yields, preserves 
exosome integrity, however it also precipitates protein aggregates and other materials as 
lipoproteins. The solely polymer reagent can interfere with downstream analysis as mass 
spectrometry [49–51]. 
Recently, microfluidic techniques have been used to isolate exosomes. This method is 
based on specific binding of exosomes to antibody coated surfaces starting from very small 
sample volumes. The fluid is pumped through a chip, resulting in exosome isolation. Microfluidic 
devices isolate exosomes in cost-effective manner and rapidly, with high sensitivity. As microfluids 
are recent, it still lacks validation and large scale tests. The smaller starting volume is another 
important issue when using this method, especially in the clinical scale exosome isolation [49–51]. 
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2. Alzheimer’s disease overview 
 Alzheimer’s disease (AD), first described by Alois Alzheimer in 1907 is a multifactorial 
disorder like most of the neurodegenerative diseases [52]. Nowadays, it is the most prevalent 
neurodegenerative disease worldwide estimated to affect 46 million people in 2015 and it is 
expected to reach the double by 2030 and triple by 2050 [53–55]. AD mainly affects individuals 
between ages of 60 and 85 years, representing a major public health challenge with huge impacts 
on patient’s quality of life, but it also represents a major economic problem [53–55]. In Portugal, 
AD cases are increasing, in 2013 it represented from 50% to 70% of dementia cases and affected 
around 160 287 individuals [56].  
AD is characterized by progressive cognitive decline, starting with memory loss and 
progressive hindering of daily activities performance, until language, perception and orientation 
impairment. In late stages of disease, individuals lose autonomy and become completely 
dependent on others. Neurodegeneration starts about 20 to 30 years before clinical symptoms 
but typically AD is diagnosed in later stages of disease and, in some cases, it can even be 
misdiagnosed due to overlap of symptoms of other diseases [57, 58]. There is a huge need for 
reliably biomarkers to assist in AD diagnosis in asymptomatic stages which will permit an earlier 
intervention with consequent improving of patient’s health and quality of life.  
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2.1. Alzheimer’s disease neuropathological hallmarks 
Alzheimer’s disease major hallmarks are neurofibrillary tangles (NFTs) and senile plaques 
(SP). 
NFTs were described as fibrous inclusions inside perikaryal cytoplasm of pyramidal 
neurons (Figure 4) [58]. NFTs are composed by paired abnormal fibrils (helical filaments), formed 
mainly by hyperphosphorylated and misfolded Tau proteins [59] and for other proteins as 
ubiquitin [60, 61], cholinesterase [62] and  amyloid beta peptide (Aβ) [63]. Tau belongs to the 
family of microtubule proteins and the interaction between Tau and microtubules is highly 
regulated by phosphorylation. Excessive phosphorylation affects Tau interactions [64].  
NFTs are initially distributed along entorhinal cortex and hippocampus (medial temporal 
lobe) [65] and then extend to primary motor, sensory and visual areas [66]. NFTs extend and 
distribution are correlated with AD degree of dementia and disease duration. Neurofibrillary 
degeneration on medial temporal lobe can lead to the initial episodic memory impairment and 
progressive neurodegeneration in other areas, such as prefrontal cortex or anterior temporal 
cortex, associated respectively to executive dysfunctions and semantic memory impairment [66–
69].  
 
Figure 4. Immunohistochemical preparation of temporal cortex of a patient with Alzheimer's disease. Red arrow points for neurofibrillary tangles and black arrow points for senile neuritic plaques. Adapted from: [58].  
SPs are another AD hallmark (Figure 4). These are mainly composed by atypical 
extracellular deposition and accumulation of Aβ 1-40 or 1-42 which are products of normal 
Alzheimer’s amyloid precursor protein (APP) processing. The Aβ1-42 is highly hydrophobic and 
fibrillogenic so it is the main component of SPs [70]. Central core of plaques is composed by a 
mass of extracellular amyloid, surrounded by dystrophic neurites (neuronal, astrocytic, microglial 
processes and paired helical filaments) supporting the Aβ potential for neurotoxicity [71, 72].  
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Amyloid plaques accumulate mainly in isocortex, at basal portions of temporal, frontal and 
occipital lobes extending then to association areas and primary isocortical areas sometimes 
without exclude cerebellum and basal ganglia [66].  
Besides the two main hallmarks, other morphological alterations which have an impact on 
cognitive performance are neuropil threads, resulting from breakdown of dendrites and axons, 
and dystrophic neurites [58, 73]. Additionally, AD brains face cerebral cortical atrophy with 
impairment of primary motor, sensory and visual areas, hippocampus atrophy and loss of brain 
tissue accompanied by lateral ventricles dilation [58]. 
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2.2. FAD and sporadic AD 
The majority of AD cases have an onset after 65 years and are considered late onset AD 
(LOAD) cases. Few cases appear between ages of 30 and 65 and are known by early onset AD 
(EOAD) cases. Etiologically, AD can be considered familiar (FAD), when various individuals of the 
same family are affected by Mendelian inheritance, or sporadic AD (SAD) cases, without familiar 
cases. Most of FAD cases are EOAD and most of LOAD cases are sporadic. FAD is characterized by 
mutations in APP, presenilin 1 (PS1) and presenilin 2 (PS2) [74].  
In humans, the APP gene is located on chromosome 21 (21q21.3) and contains at least 18 
exons [75–77]. APP is a type-I transmembrane protein that belongs to a three-member family of 
homologs identified in mammals: APP [78, 79], APP like protein 1 (APLP1) [80] and 2 (APLP2) [81, 
82]. These members share a conserved structure as E1 and E2 domains, a short C-terminal 
intracellular tail and a large extracellular domain however Aβ domain is specific of APP and do not 
exist in the other homologs (reviewed in [83]). APP autosomal mutations are rare and mainly 
located in exons 16 and 17, located near the α-secretase cleavage site (within Aβ sequence) or 
near γ-secretase site which alter APP processing and increase Aβ1-42 production [84].  
The majority of FAD cases is caused by PS1 and PS2 autosomal mutations which are 
related with increase production of Aβ1-42, the main component of SPs [74]. PS1 and PS2 genes 
have a similar structure although PS1, located on chromosome 14, encodes the catalytic core of γ-
secretase, and PS2, located in the chromosome 1, codifies for active sites of the γ-secretase 
complex [85, 86]. Recently, a PS1 loss of function mutation was identified as correlated with 
overproduction of Aβ1-43 which is highly amyloidogenic [87].  
SAD results from a combination of genetic and environmental factors. Apolipoprotein E 
(APOE) alleles presence is the highest risk factor for SAD, especially APOE4 alleles increase which 
encodes apolipoproteins in brain [88], but APOE2 has a protective role [89]. APOE genes encode 
for lipoprotein binding amyloid peptides. Besides APOE4 allele, environmental risk factors as low 
educational levels, hypertension, high cholesterol levels, smoking, pesticides, traumatic brain 
injury and depression also contribute to SAD. Protective AD factors may be physical exercise, 
hormonal replacement therapy and moderate alcohol consume [90]. 
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2.3. Alzheimer’s amyloid precursor protein 
2.3.1. APP processing 
APP can be proteolytic cleaved by two pathways: the non-amyloidogenic pathway, 
mediated by α- and γ-secretases (Figure 5A), or the amyloidogenic pathway where Aβ generation 
occurs by sequential cleavage of β- and γ-secretases (Figure 5B).  
In the non-amyloidogenic pathway, APP is cleaved by α-secretase within the Aβ domain 
(between Lys16-Leu17 bond) [91, 92], releasing the large soluble ectodomain sAPPα and generating 
the membrane bound carboxy-terminal fragment APP-CTFα or C83 [93], which lacks the amino 
terminal portion of Aβ. C83 can be further cleaved by γ-secretase liberating small hydrophobic 
peptides, called P3 fragments [94] and the APP intracellular domain (AICD) [95]. APP processing 
by α-secretases is expected to be neuroprotective as precludes Aβ formation and originates P3 
fragment that although found in diffuse amyloid plaques has been considered to be non-
pathogenic [96–98].  
 
 
 
 
 
 
 
 
 
Figure 5. APP processing. A. Non-amyloidogenic processing of APP. APP is cleaved by α-secretase in amyloid peptide 
sequence originating sAPPα and αCTF. Then, αCTF is cleaved by γ-secretase producing p3 and AICD. B. Amyloidogenic 
processing of APP. APP is cleaved by β-secretase generating sAPPβ and βCTF. γ-secretase cleaves βCTF in AICD and in 
neurotoxic Aβ specie. APP: amyloid precursor protein; Aβ: amyloid beta peptide; sAPP α/β: soluble amyloid precursor 
protein α/β; α/βCTF: carboxy-terminal fragment α/β; AICD: APP intracellular domain. Arrows highlight cleavage sites of 
secretases. 
 
A. Non-amyloidogenic pathway B. Amyloidogenic pathway 
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α-secretases are plasma membrane proteases [99], more precisely zinc 
metalloproteinases [100]. Several members of ADAM family (“a desintegrin and 
metalloproteinase”) can act as α-secretases: ADAM9 [101, 102], ADAM10 [102, 103], ADAM17 
[102, 104], ADAM19 [105]. ADAM17 has found to play a crucial role in APP regulated cleavage 
[104], especially in neurons [106] as well as ADAM9 that when inhibited stops the regulated 
production of sAPPα [107]. ADAM10 seems to be responsible for the characteristic constitutive α-
secretase cleavage of APP, in various cell lines [107], including in neurons. ADAM9 [108] and 
ADAM19 [109] are also expressed in human brain. 
The amyloidogenic pathway is mediated by β-secretase cleavage of APP at amino terminal 
with the release of sAPPβ ectodomain and the formation of membrane-bound APP-CTFβ or C99 
that is further processed by γ-secretase leading to Aβ generation and a long AICD (Figure 5B).  
The β-site APP cleaving enzyme 1 (BACE1) was the first transmembrane aspartyl protease 
found, highly expressed in brain [110–115]. It cleaves APP preferentially at Asp1 and Glu11, its 
optimal activity is at low pH and the enzyme is preferentially located in acidic compartments as 
early Golgi, late Golgi and endosomes, besides of plasma membrane [111, 116–118]. Beyond 
BACE1, cathepsin B was also proposed to be a β-secretase as its inhibition decreased Aβ 
generation in neuronal chromaffin cells and in mice [119, 120]. 
γ-secretase is a high molecular weight aspartyl protease complex composed by four 
transmembrane components: PS1 and PS2 with two aspartyl residues that are part of the catalytic 
domain [121, 122], and three adaptor proteins: nicastrin [123], anterior pharynx-defective 1 (APH-
1) and presenilin enhancer protein 2 (PEN2) [124, 125]. All components of γ-secretase seems to 
be essential for its function, APH-1, nicastrin and PEN2 are necessary for complex maturation, 
stability and function as it was demonstrated in a Saccharomyces cerevisiae model [126–128]. 
Nicastrin interacts with APH-1 in early assembly of γ-secretase complex [129] and PEN2 regulates 
the proteolytic processing activity of presenilins [130]. Despite of the four already described γ-
secretase components, some factors have been identified as potential new components as CD147 
[131], TMP23/p21 [132] and an γ-secretase activating protein (GSAP) [133]. 
γ-secretase cleaves the products of α- and β-secretases at various sites, preferentially 
within transmembrane domains near cytoplasmic border of PM. The clear majority of species 
produced by γ-secretase processing are Aβ1-40 and Aβ1-42 and respective AICD’s.  
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2.3.2. APP intracellular trafficking 
Full length APP is synthetized in the endoplasmic reticulum, transported through Golgi to 
trans-Golgi network (TGN) (Figure 6) where most part of post translational modifications occur 
such as phosphorylation, N- and O-glycosylation and sulfation [134]. A small portion of APP is 
transported into TGN vesicles to plasma membrane where APP can suffer α-secretase cleavage, 
producing sAPPα, or be reinternalized and cleaved in endosomes generating Aβ peptide and other 
products that can be after transferred to MVBs [135]. Aβ peptides can also be generated in 
various cell compartments as endoplasmic reticulum, Golgi apparatus, TGN, endosomes and 
lysosomes, in the presence of β and γ-secretases which contributes to intracellular accumulation 
of Aβ. Evidences suggest that APP amyloidogenic processing occurs mainly in lipid rafts of 
intracellular organelles [135–138]. Some MVBs can fuse with lysosomes to degradation and 
others fuse with PM, releasing ILVs as exosomes. Aβ can accumulate in some ILVs so can be 
released into exosomes. Various studies corroborate the presence of Aβ and other cleavage 
products inside exosomes [139] as described in topic 3. 
 
Figure 6. APP intracellular trafficking. New synthetized APP mature and is transported through secretory pathway, from endoplasmic reticulum to Golgi and TGN to PM where APP can be non-amyloidogenic processed. APP full length at PM can be internalized and further recycled or traffic to late endosomes and lysosomes to be degraded or amyloidogenic processed. APP: Amyloid precursor protein; Aβ: Amyloid beta peptide  
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2.4. Amyloid cascade hypothesis 
Amyloid cascade hypothesis considers that amyloid peptide accumulation in brain 
parenchyma is the trigger event for a neurodegenerative cascade that culminates into dementia 
(Figure 7). This is supported not only by autosomal dominant mutations in PS1 and PS2 which 
impair APP metabolism and cause EOAD, but also by mutations at APOE gene. APOE alleles 
appear to have distinct impact on AD pathology. APOE2 proteins mediate clearance of Aβ but the 
presence of allele APOE4 is correlated to increased risk for develop sporadic AD, as already 
mentioned. Many other mutations can contribute to AD as mutations in the gene that encode Tau 
protein. These mutations were initially found in patients of frontotemporal dementia which is a 
neurodegenerative disorder characterized by Tau deposition with formation of NFTs and neuronal 
loss, but without amyloid plaques accumulation [140–142]. Therefore, it is thought that NFTs 
appear after SPs. This is supported by the fact that transgenic mice overexpressing human APP 
and Tau have increased formation of Tau tangles but do not exhibit alterations in SPs [143]. 
Despite of all efforts made, it is still uncertain the exact mechanism linking Aβ deposition and 
NFTs.  
Neurotoxicity of Aβ peptides is sustained by small diffusible Aβ oligomers which assemble 
when fibril formation is not possible and impair synaptic plasticity and memory during early stage 
of AD [144]. Soluble oligomers formed after Aβ plaques formation also contribute for Aβ toxicity, 
impairing long term potentiation (LTP) in vivo, required for memory formation, and decreasing 
the number and function of synapses [145]. Different forms of Aβ oligomers were identified in 
human brain and transgenic organisms [145–147]. Recently, soluble oligomers were quantified in 
post-mortem brain tissues from healthy subjects and patients with dementia, and although 
similar plaque densities were identified in both cases healthy subjects had a weaker correlation 
between oligomers and plaque deposition when compared with AD patients [148]. Amyloid 
cascade hypothesis highlights the role of Aβ and its contribution to AD disease type dementia. 
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Figure 7. Schematic representation of the amyloid cascade hypothesis and the major pathogenic events leading to Alzheimer’s disease. Adapted from [149]. Aβ: Amyloid beta peptide; AD: Alzheimer’s disease; APOE4: Apolipoprotein allele 4; NFT: Neurofibrillary tangle; PS1/2: Presenilin 1 or 2 genes. 
 
 
 
 
 
 
 
 20  
2.5. Neurochemical dementia diagnostics in Alzheimer’s disease 
As already mentioned, AD neuropathological alterations begin several years before onset 
of symptoms and AD clinical diagnostic [150, 151]. During the preclinical AD stage, pathological 
alterations start in the medial temporal lobe and extend to neocortex [152, 153]. Then, AD can 
evolve to a prodromal stage, with mild symptoms presentation, and to the symptomatic stage 
characterized by dementia. Dementia is sometimes preceded by the mild cognitive impairment 
stage (MCI) which includes memory impairment [154]. 
A conclusive AD diagnosis based on clinical symptoms is particular difficult in early stages. 
In the last few years, efforts have been made to identify new biomarkers to enhance accuracy of 
AD diagnosis [155, 156]. The neurochemical based dementia diagnostic (NDD) is particular useful, 
since it allows to distinguish AD from other forms of dementia [157]. 
Not surprisingly, Tau, Tau hyperphosphorylated form and Aβ1-42 were the first three 
biomarkers, identified in cerebrospinal fluid (CSF) [66], and nowadays, these are yet the most 
established in AD neurochemical diagnostic. Decreased levels of Aβ1-42 in CSF of AD patients 
were identified by various groups [158, 159]. A decrease in Aβ1-42  was also identified in patients 
with Creutzfeldt-Jakob disease [160] and in cases of bacterial meningitis [161]. Thus, the use of 
these biomarker in combination with other biomarkers will increase AD diagnostics sensitivity and 
specificity. Levels of Aβ1-42 in CSF permitted to distinguish AD patients from control non-
dementia patients, with sensitivities and specificities around 80% [159, 162, 163]. In addition to 
Aβ1-42, several other peptides were found abundant in CSF: Aβ1-37, Aβ1-38, Aβ1-39 and Aβ1-40 
oxidized form, and indeed concentrations of Aβ1-38 and Aβ1-40 oxidized peptides were increased 
in AD patients [164, 165]. Hence other APP fragments in CSF are being explored as potential AD 
biomarkers. It was already reported increased CSF levels of sAPPα and sAPPβ in AD and MCI-AD 
with a sensitivity of 75% when compared with controls, also showing their potential as biomarkers 
[166].  
Various studies supported the use of Tau CSF levels as a biomarker as it could predict AD 
with sensitivities of 81% and specificities of 92% [167, 168]. Increased levels of CSF Tau were also 
found in other dementias such as vascular dementia and frontotemporal dementia [169, 170], but 
the concentration values of phosphorylated forms of Tau (p-Tau) in CSF are specifically related to 
AD. In particular, increased levels of p-Tau 181 were found in CSF of AD patients [171], similarly  
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p-Tau 199 and p-Tau 231 increased levels were identified as putative biomarkers for AD diagnosis 
[172, 173].  
Diagnostic biomarkers combination will enhance AD diagnosis (Table 1). This diagnosis 
does not exclude the need for cognitive evaluation of the patients and of the use of imaging 
techniques. In addition to CSF neurochemical biomarkers, AD diagnostics should also include 
magnetic resonance imaging and other imaging biomarkers to enhance diagnosis accuracy [174].  
 
Table 1. Usefulness of combinatorial CSF neurochemical-based biomarkers. AD: Alzheimer’s disease; NAD: Non-Alzheimer’s disease types of dementia; MCI: Mild cognitive impairment. 
CSF Biomarkers 
combination Diagnosis Sensitivity Specificity Study 
Aβ1-42 and total Tau AD versus NAD 85% 58% [162] 
Tau and Aβ1-42/Aβ1-40 AD versus NAD 81% 87% [175] 
p-Tau 181 and Aβ1-
42/Aβ1-38 AD versus NAD 94% 85% [176] 
Tau, p-Tau 181 and Aβ1-42 AD versus MCI 68% 97% [177] 
Aβ, Tau and p-Tau AD versus controls >80% >80% [178] 
   
The CSF-based biomarkers are currently the gold standard to assist AD diagnosis, 
however, this involves a lumbar puncture, which brings some limitations, as an invasive procedure 
and as a screening tool. Hence, blood-based biomarkers are receiving increased attention, as they 
can be easily obtained, proportionate early diagnosis and better disease management. Blood has 
appropriate conditions to be a great source of biomarkers for AD: some brain-derived products 
circulate in the bloodstream due to direct contact with CSF, brain-derived products are 
predominantly release to blood-brain barrier rather than into the CSF and Aβ was detected in 
blood as result of Aβ clearance from the brain parenchyma [179, 180]. Several forms of Aβ (1-
37,1-38, 1-39, 1-40, 1-42) were already identified in plasma and even a new form never found in 
CSF: Aβ2-40 [181]. Increased plasma levels of Aβ1-40 were found in individuals with higher risk to 
develop dementia and increased baseline concentrations of Aβ1-40 and Aβ1-42 for AD patients 
[182, 183]. [184]. In addition, an elderly cohort study showed the potential of plasma Aβ1-
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42/Aβ1-40 ratios to identify elderly subjects at higher risk to develop mild cognitive impairment 
[185]. However, a decrease in plasma Aβ1-42 was reported for AD patients [186] and no 
differences were found between serum levels of AD Aβ1-42 of AD patients and healthy individuals 
[184]. In addition, low plasma Aβ1-42/Aβ1-40 ratios were identified in AD patients [187]. 
Furthermore, the interest of sAPPα and sAPPβ as blood-based biomarkers is increasing 
however studies are still scarce. Decreased levels of sAPPβ were already found in plasma of AD 
patients when compared with controls or frontotemporal dementia individuals however it were 
not identified significant differences for sAPPα levels [188].  
 Controversial data on the potential of Aβ and sAPP as blood based biomarkers reflects the 
need for additional studies and methodologies to validate their potential as peripheral biomarker 
candidates for AD. 
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3. Exosomes in Alzheimer’s disease 
Exosomes have a great potential due to their diversified content and for their presence in 
various body fluids. Exosomes became more recently to be explored in the context of 
neurodegenerative diseases, as Alzheimer’s and Parkinson’s diseases, as potential sources for 
biomarkers useful either for diagnostic or therapeutics without exclude their contribution to 
elucidate disease mechanisms. In AD, exosomes have been addressed to elucidate Aβ formation, 
the spreading of amyloidogenic proteins but also the role of tau into exosomes (Figure 8). 
 
3.1. Exosomes carrying Aβ: Neuroprotection or neurotoxicity? 
The exact role of exosomes in AD is unclear. It was shown that Aβ1-42 peptide was 
enriched in MVBs of neurons [189] and of different cell models [139] and that it could be secreted 
into the extracellular space via exosomes. Further, it was also observed an enrichment of the 
exosome marker Alix around small SPs and into large diffuse plaques in brains of post-mortem AD 
patients which suggests that Aβ release into exosomes can possibly contribute for plaque 
formation and the progression of the disease [139]. In addition, microglia surrounding SPs 
appears to play a role in neurodegeneration by secreting exosomes containing Aβ1-42 [190]. 
Besides full-length APP (flAPP) some APP metabolites were found to be carried by 
exosomes such as APP CTFs and AICD [191] however the involvement of exosomes in secretion of 
amyloidogenic species is not well clarified. Exosomes secreted by brain mice mimicking AD, 
exibited higher levels of flAPP and APP CTFs than wild type mice which suggest that AD enhances 
accumulation of these proteins into exosomes [192]. APP CTFs and Aβ secretion into exosomes 
can be a protective mechanism for cells, relieving toxicity, or alternatively, potentially harmful 
since the secretion of exosomes enriched with APP CTFs and Aβ can contribute to the formation 
of SPs and also for the spread of amylogenic material between cells [192]. In addition, it was also 
found Aβ species, CTFs and increased levels of sAPPα into exosomes secreted by a human cell line 
expressing wild type APP in γ-secretase inhibition conditions. These exosomes also contained 
BACE, PS1, PS2 and ADAM10 which suggests that APP can be cleaved into exosomes and not only 
at the PM [193].  
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Additional, Aβ1-40 binding, conformational changes and aggregation were determined to 
be favoured by high membrane curvatures, for example on exosomes, and high abundance of 
membrane proteins [194].  
Higher levels of BACE-1, γ-secretase, sAPPβ, sAPPα, Aβ1-42, p-Tau 181 and p-Tau 396 
were detected into exosomes derived of astrocytes AD patients. Levels of P-T181-Tau, P-S396-Tau 
and Aβ1-42 were also increased in neuronal exosomes derived from plasma of AD patients [195].  
Moreover, it was demonstrated in vitro that Aβ induces neuronal death of astrocytes surrounding 
SPs [196]. These secreted exosomes can induce apoptosis in astrocytes not exposed Aβ by being 
taken up by these cells which might represent a new mechanism for apoptosis induction by Aβ 
[196]. 
Despite the harmful effects of exosomes in the spread of amylogenic substances some 
beneficial actions for exosomes can also be described. Neuronal exosomes were uptake by 
microglia, contributing for Aβ clearance from extracellular space [197]. Moreover, the clearance 
of Aβ promoted by secreted exosomes of activated microglia reduces the inflammation around 
senile plaques  and APP transgenic mice injection of exosomes resulted in a reduction of Aβ levels 
and Aβ deposits which support that exosomes can capture Aβ [197]. In addition, it was observed 
that exosomes infusions can sequester Aβ peptides which is mediated by exosome surface 
proteins as cellular prion protein (PrPC). This may neutralize synaptic plasticity dysfunctions 
normally induced by Aβ [198].  
Some Aβ degrading enzymes were found into exosomes, highlight their beneficial role in 
AD. A part of insulin degrading enzyme (IDE), one of the proteases responsible for Aβ extracellular 
degradation, was found into secreted exosomes [199]. In addition, statins administration can 
enhance exosome secretion carrying IDE, contributing to Aβ clearance, however the mechanism is 
still unknown [200]. Neprilysin, another Aβ degrading enzyme, is also carried by exosomes and 
internalization of these lead to a reduction of extracellular and intracellular levels of Aβ [201].  
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The potential of exosomes as a therapeutic approach is highly relevant and is favoured by 
the capacity of exosomes to cross the blood brain barrier [202–204]. Exosome mediated delivery 
of short interfering RNA (siRNA) to knock down beta secretase 1 (BACE1) enzyme is an example of 
the potential use of exosomes in this area. Exosomes can be a suitable tool for gene therapy by its 
capacity to deliver nucleic acids, specially targeted exosomes, which perform deliveries with good 
specificity [202]. As neuronal exosomes carry Aβ and contribute for amyloidogenesis it would be 
also of beneficity reduce exosome secretion. Inhibition of nSMase 2, the enzyme responsible for 
ceramide generation leads to a decrease of brain and serum exosome secretion, reduces SPs 
formation and neuronal apoptosis [205]. Moreover, this hypothesis is supported for further 
studies that observed an exosome secretion increase in serum of mice treated with ceramide 
[206]. It remains to be clarified if increased exosome secretion is in fact involved in SPs formation.  
Figure 8. Content of AD nervous system cell-derived exosomes. Exosomes secreted by neurons, microglia and astrocytes contain several AD intermediators such as Aβ and sAPPα/β and enzymes involved in APP processing as γ-and β-secretases. APP: amyloid precursor protein; Aβ: amyloid beta peptide; AICD: APP intracellular domain; CTF: carboxy-terminal fragment; sAPP α/β: soluble amyloid precursor protein α/β; p-Tau: phosphorylated tau. 
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3.2. Tau and exosomes in AD 
Tau species of 35-40 kDa were shown to be secreted into extracellular space by exosomes 
and Tau phosphorylated in threonine 181 was present in exosomes isolated from CSF of AD 
patients [207] or plasma neuron-derived exosomes [195]. It was suggested that oligomeric Tau 
species can be transported by exosomes and that this process could contribute to fibrillar 
formation in other cells [207]. Extracellular Tau truncated at C-terminal and lacking the 
microtubule binding region (MTBR) is the major Tau specie released by neurons to extracellular 
space and a minor portion of this specie can also be detected into exosomes [208].  
Recently, it was observed that the depletion of microglia and inhibition of exosome 
secretion results in suppression of Tau propagation between neurons. Thus, microglia was 
hypothesized to contribute for Tau rapid spread, from entorhinal cortex to the dentate gyrus, by 
phagocytizing Tau and then secreting it into exosomes. This way, it emerges a new kind of 
transport for Tau that explains non-synaptic propagation [209].  
Tau secretion into exosomes seems to correlate with a relevant pathogenic role in disease 
since exosomes can carry Tau forms that can act as seeds of Tau aggregation and misfolding in 
recipient cells, as exosome aggregated Tau and phosphorylated Tau [210]. 
Nonetheless, Tau secretion into exosomes is still controversial. Some research groups did 
not find Tau into exosomes released from SH-SY5Y [211], medium of cultured rat cortical neurons 
[212] and from various other cell lines and also body fluids [213]. 
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3.3. Exosomes as biomarker resources in AD 
Exosome potential as biomarker resources in AD have been addressed in various body 
fluids, especially in exosomes isolated from serum, plasma and CSF. 
Elevated levels of blood exosomal p-Tau 396, p-Tau 181 and Aβ1-42 were observed in 
preclinical subjects up to 10 years before AD diagnosis and Aβ1-42 levels progressively increased 
from asymptomatic stage to AD diagnosis, which suggests its potential as a progression biomarker 
[214]. Levels of these three proteins could predict the development of AD before clinical 
diagnostic with a sensitivity of 96% [214]. As already mentioned, high levels of BACE1, γ-
secretase, sAPPα and sAPPβ, Aβ1-42, p-Tau 396 and p-Tau 181 were found in plasma neuronal-
derived exosomes from AD patients [195]. The p-Tau 181 protein was also found in exosomes 
derived from CSF of early AD patients [207]. 
Neuronal-derived plasma exosomes from AD patients exhibited distinct phosphorylation 
patterns of the adaptor protein receptor substrate 1 (IRS-1), in preclinical AD cases supporting its 
potential as an AD exosomal biomarker [215]. In fact, the brain tissues of AD individuals typically 
exhibit altered phosphorylation pattern of IRS-1 and IRS-2, mimicking insulin resistance [215]. 
Altered levels of diverse lysosomal proteins into plasma exosomes were also identified such as 
high levels of cathepsin D and LAMP-1 and lower levels of heat shock protein 70 (Hsp70) [216]. 
These different protein alterations were detected 10 years before AD being diagnosed and may 
be a result of lysosomal dysfunction observed in AD [216]. In addition, P-T181-Tau, P-S396-Tau, 
Aβ 1-42, neurogranin and RE1-Silencing Transcription factor were also identified as exosomal 
biomarkers with high sensitivity for distinction of controls from AD patients and evolution of MCI 
to AD [217]. 
Besides protein content, exosome genetic cargo might also represent novel biomarker 
candidates, special miRNA. Various neurodegenerative diseases as AD present altered miRNA 
expression patterns. A set of twenty miRNAs derived of from plasma exosomes were identified as 
potential biomarkers for AD [218]. Further, microRNA 193b was found into exosomes isolated 
from CSF of MCI or AD patients with stablished [219]. About 16 exosome miRNAs from serum 
were considered potential AD biomarkers, presenting high sensitivity (87%) and specificity (77%), 
and correlating age, sex and APOE4 allele status as risk factors to predict AD [220]. Recently, 
miRNA 34a was also identified as a potential target for AD therapeutics [221]. This miRNA is 
typically overexpressed in AD patients and AD transgenic mice and is known to regulate various 
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cellular processes as synaptic plasticity by repressing some pre-synaptic proteins and post-
synaptic ion channel proteins and energy metabolism. The latter event may related with 
repression of some oxidative phosphorylation proteins expression, overall mitochondria activity 
and resting state network activity [221]. Neurons secrete exosomes with miRNA 34a which can 
contribute to AD progression, through impairment of resting state network activity and by 
worsening memory capacities due to dysregulation of many genes in brain neighbour cells [221]. 
Interestingly, ADAM 10 gene was also identified as a target for miRNA 34a, supporting that ADAM 
10 gene decreased expression by miRNA 34a can increase Aβ secretion and contribute for AD 
progression [221]. Taken together data suggest that exosomes containing miRNA can be useful for 
AD diagnosis and therapeutic strategies. 
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Aims of the thesis  
 
Exosomes are released by various cell types, are present in several biofluids [222–229] 
and participate either in physiological and pathological processes [197, 206, 230–232], thus 
represent a potential source for identification of novel AD biomarker candidates.  
Nonetheless, exosome isolation from biofluids is still a challenge topic. The most used 
technique is differential centrifugation however has low recovery-rates, is time-consuming, is not 
fully reproducible between labs [233] and can compromise exosome integrity [49–51]. To 
overcome this issues the use of precipitation polymer-based reagents is increasing. The main 
advantages of these reagents are easy handling, good exosome yields and no need of special 
equipment. Column-based protocols are also very useful as provide exosome isolation with 
greater purity than precipitation-based methods [51, 234]. Therefore, the first aims of this thesis 
were to: 
- Optimize and compare the performance of 3 commercial kits for exosome isolation from 
different body fluids (two exosome precipitation-based kits and one column-based 
method); 
- Characterize exosome samples in terms of size, stability, morphology and particle yield. 
 
After exosome isolation protocols optimization, the potential of exosomes as biomarker 
resources for AD was addressed by evaluating soluble APP forms in cognitive demented cases. 
The value of sAPP as biomarker as already been tested in CSF [166], plasma [188] and plasma 
derived-exosomes [195] but not in serum or serum-derived exosomes. Hence, the final goal of this 
thesis was to: 
- Evaluate the potential of sAPPα and sAPPβ in serum and serum-derived exosomes in 
dementia cases. 
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Chapter 2. Exosome isolation from different biofluids 
  
BLANK 
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2.1.    Materials and methods 
 
Biofluids preparation 
Serum, plasma were obtained from a pool of samples of normal individuals, and CSF from 
a pool including normal and patient cases. Blood samples were collected in EDTA tubes, 
centrifuged at 1800g during 15 min for plasma and centrifuged at 2000g during 15 min for serum. 
CSF was obtained by lumbar punction and centrifuged at 3000 rpm for 5 min. All samples were 
aliquoted and stored at -80ºC. 
The study was approved by Ethics Committee for Health of the Central Regional 
Administration of Coimbra (CES da ARS Centro, protocol No. 012804-04.04.2012) and by the 
National Committee for Data Protection (Authorization Nº 369/2012). 
 
Exosome isolation from serum and plasma 
Exosomes were isolated using three commercial kits: Total Exosome Isolation from serum 
(Invitrogen) (TEI), ExoQuick Serum Exosome Precipitation Solution (System Biosciences) (ExoQ) 
and Exo-spin Blood Exosome Purification Kit (Cell guidance systems) (ExoS) (Figure 9).  
TEI and ExoQ are exosome precipitation kits based on the use of water-excluding 
polymers as polyethylene glycol. These polymers bind water molecules leading to the exclusion of 
less soluble components. Prior to sample incubation with polymers, the biofluid is centrifuged to 
remove cells and some subcellular components. After incubation at 4ºC with polymer reagents, 
the mixture is centrifuged at low-speed [50, 51]. 
ExoS is a column-base method which comprises a precipitation-step followed by exosome 
sample purification by SEC. In this method, it is used a column coated with porous polymeric 
beads containing ciliated micropillars. Components with lower hydrodynamic diameters (about 40 
to 100 nm) are retained and take more time to pass through wired area. Higher particles elute 
first as they are not retained in nanocilia pores [50, 51]. 
All exosome isolations were prepared according to manufacturer’s instructions with 
minor modifications (Figure 9). For all cases, exosome isolation was carried out in triplicate. 
Exosome purification from TEI and ExoQ was carried out from a starting volume of 250 μl of 
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serum and plasma, except for plasma isolation using ExoS that was performed from a starting 
volume of 200 μl, as recommended by the manufacturer. 
After all exosome isolation procedures, exosome suspensions were divided in half into 
two tubes. To one part, 100 μl RIPA buffer (Sigma-Aldrich) was added to lysis exosomes and 
samples prepared for Western blot. The other part remained in PBS for size, stability and particle 
quantification analysis. Exosome suspensions were freeze at -20ºC, except for transmission 
electron microscopy (TEM) procedure as new fresh exosome samples were prepared. 
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Figure 9. Exosome isolation workflow. Serum and Plasma derived exosomes were isolated using precipitation-based reagents Total Exosome Isolation from serum (Invitrogen) (TEI) and Exoquick Serum Exosome Precipitation Solution (ExoQ) and the column-based method Exo-Spin Blood Exosome Purification kit (ExoS). *The starting volume for plasma exosome isolation using ExoS was 200 μl as recommended by manufacturer. Exosome extraction from pooled CSF was also performed using equivalent methods.  
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Exosome isolation from CSF 
Exosome isolation from CSF was performed using Total Exosome Isolation from cell 
culture media (Invitrogen) (TEI), ExoQuick-TC exosome precipitation solution (System Biosciences) 
(ExoQ) and Exo-spin Exosome Purification Kit for cell culture media/urine/saliva and other low-
protein biological fluids (Cell guidance systems) (ExoS). All exosome isolations were performed in 
triplicate. Exosome isolations were performed according to manufacturer instructions with some 
minor modifications (Figure 9). For all cases, a starting volume of 1 ml of pooled CSF was used.  
All exosome suspensions were divided in half into two tubes after exosome isolation 
procedures as already described for serum and plasma exosome suspensions. Finally, exosome 
samples were freeze at -20ºC, except for TEM as described above. 
 
Exosomes size distribution and zeta potential analysis 
To evaluate particle size and stability of exosomes in solution, dynamic light scattering 
and Zeta Potential measurements were performed using Zetasizer Nano ZS (Malvern Instruments, 
Paralab, Portugal) and Zetasizer software 7.12.  
Dynamic light scattering (DLS) is a wide use method to measure the size of particles and 
molecules in suspension. When light hits in a particle, the light scatter in all directions as result of 
the interaction between light and the electric field of the particle. However, the scattering 
intensity of a particle is not constant since these moves in random way (Brownian motion) in 
solution. Therefore, DLS measures the speed of Brownian motion of particles. The speed of 
Browian motion is influenced by size of particles, viscosity and temperature. Smaller particles 
have a fastest Browian motion and larger ones have slower motions. These speeds are then 
converted in particle size by Stokes-Einstein equation. The particle size determined by DLS 
corresponds to the hydrodynamic diameter which depends of particle size, particle surface 
structure and the presence of ions in the solution [235–237].  
To measure particle sizes and determine zeta potential, exosome suspensions were 
diluted at 1:1000 in ultrapure water and sonicated during 10 min in a water-bath at room 
temperature (RT). Sonication was performed to reduce exosome aggregation which influences 
size measurements by DLS. For each exosome sample three measurements (technical replicates) 
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were carried out for all experimental replicate. The following settings were used: Refractive Index 
= 1.330, viscosity = 0.887, temperature = 25ºC. 
 
Transmission electron microscopy 
Nano-sized particles as exosomes are outside optical microscopy resolution. Therefore, 
electron microscopy is the optimal choice since it can achieve resolutions in the order of few 
angstrom, allowing to study ultrastructure of organelles, for example. Instead of using a light 
source like optical microscopy, electron microscopy uses a cathode as an electron source. 
Tungsten filaments when heated at vacuum emit electrons at a constant accelerating voltage, so 
these filaments are widely used as electron sources. Then, electron beam is focused in a thin 
beam by condenser electromagnetic lens in the plane of specimen or very near. In transmission 
electron microscopy, the electron beam crosses the specimen despite some electrons are 
scattered, also depending of specimen density. Electron beam that crossed the specimen then 
crosses electromagnetic objectives lens and multiple electromagnetic lenses, to focus and 
magnify the virtual image. Finally, the beam hit a fluorescent screen where electrons are 
converted to light and the image collected by a charge-coupled device (CCD) camera [238–240]. 
To obtain high contrasted images negative staining is a god choice. It is based on deposition of 
heavy metals contained in a staining solution. Instead of binding to the specimen, heavy metals 
are deposited around the sample creating “shadow” zones [239]. 
Freshly exosome isolations were performed for TEM visualization as described above with 
minor modifications. For serum, plasma and CSF samples isolated using ExoQ and TEI the 
exosome pellet was directly fixed in 200 μl of 2% paraformaldehyde. For exosome isolations 
derived from serum, plasma and CSF isolated using ExoS exosomes were eluted in 100 μl of PBS 
and then mixed with 100 μl of 4% paraformaldehyde to a final concentration of 2% 
paraformaldehyde. In all cases, exosome suspensions of 20 μl were allowed to adsorb in 75 mesh 
Formvar/carbon coated grid (01802-F; Ted Pella), for 30 min, at RT. Grids were then washed with 
PBS (membrane side faced down) and dried using filter paper. For negative staining, exosome-
grids were transferred to a 50 μl drop of 3% phosphotungstic acid solution (pH 7) for 10 min and 
then wicked off with filter paper. TEM visualizations were performed using Hitachi H-9000 
transmission electron microscope at 300 kV and images were captured using a slow-scan CCD 
camera. 
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Exosome yield analysis 
To estimate exosome number, the colorimetric EXOCET assay (System Biosciences) was 
performed. It is based in the measurement of the enriched activity of Acetyl-CoA 
Acetylcholinesterase activity in exosomes [241]. A volume of 10 µl of exosomes suspensions in 
PBS were diluted each in 90 µl of lysis buffer. To address if the buffer interferes with the assay 10 
µl of PBS were diluted also in 90 µl of lysis buffer. Then, mixtures were incubated at 37ºC for 5 
min, vortexed and centrifuged at 1500g at RT during 5 min to remove debris. Afterwards, 50 µl of 
test sample was mixed with 50 µl of reaction buffer. Following 20 min of incubation at RT the 
absorbance of plate was read at 405 nm, using TECAN Infinite M200. The standard curve was 
created by plotting absorbance by number of exosomes.  
 
Protein quantification 
Protein quantification of all exosome suspensions was performed by colorimetric 
bicinchoninic acid protein assay, using Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific). 
BCA assay is based on the biuret reaction which consists in the capacity of amino acids to complex 
with cupric ions in an alkaline environment, producing a blue light. Then, BCA reacts with cuprous 
cations producing a strong violet light, whose intensity is proportional to the number of peptide 
bonds and can be measured at 562 nm. 
Prior to protein quantification, exosome samples ressuspended in PBS were lysed by 
adding a half volume of RIPA buffer (Sigma Aldrich) with cOmplete, Mini, EDTA-free Protease 
Inhibitor Cocktail (Roche) and incubated at RT for 5 min. All samples were sonicated for 15 
seconds. Samples of 2 μl of serum-derived exosomes or plasma-derives exosomes and 5 μl of CSF-
derived exosomes were quantified by BCA assay. Samples and standards were homogenised with 
buffers (PBS and RIPA) (Table 2) and further incubated with 200 μl of working reagent prepared in 
the proportion of 50 parts of reagent A to 1 part of reagent B. The plate was incubated at 37ºC for 
30 min and the absorbance of BCA assay was measured at 562 nm using TECAN Infinite M200.  
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Table 2. Standards used in BCA protein assay. BSA: Bovine serum albumin (2 mg/ml). 
Standard BSA (µl) Buffer (µl) Protein mass (µg) 
P0 0 50 0 
P1 1 49 2 
P2 2 48 4 
P3 5 45 10 
P4 10 40 20 
P5 20 30 40 
 
SDS-PAGE  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is the most used 
method to separate proteins from a mixture, based in protein molecular weight and charge. 
Proteins are separated through migration across gel pores when an electric field is applied. As 
different proteins contain different charges what would interfere in the running, SDS is applied to 
confer a negative charge to all proteins. One molecule of SDS can bind to two amino acid residues. 
Therefore, all proteins can migrate from negative to positive anode. Typically, before loading in 
the gel, samples are heated for few minutes with a reducing agent, as β-mercaptoethanol. These 
reagents cleave disulphide bonds to disrupt tertiary and quaternary protein structures, ensuring 
protein linearization and equal protein migration in the gel, independently of three-dimensional 
structure.  
For serum and plasma-derived exosome samples 50 μg of protein were loaded on the gel 
however for CSF samples a total volume of 100 µl was loaded since BCA quantifications for these 
samples were near zero. Samples were boiled at 99ºC for 5 min, loaded and separated in a 5-20% 
SDS-PAGE gradient gel, at constant 90 mV for about 2 to 3 hours, in Hoefer SE 600 electrophoresis 
system. The protein marker Precision Plus Protein Dual Colour Standards (1610374; Bio-Rad) was 
used. 
 
Western blotting 
Western blotting is a powerful technique to detect specific proteins with specific 
antibodies after proteins were separated according to their size and transferred to a solid support 
membrane, for example made of nitrocellulose. In the electrophoretic transference proteins 
become immobilized at respective migration positions where the gel was stopped to run. Proteins 
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were electrophoretic transferred to a nitrocellulose membranes in a wet system for 18h and at 
200 mA. After transference, the membrane could dry at room temperature. Transfer was further 
confirmed using Ponceau staining solution which is a red stain dissolved in an acidic solution. 
Ponceau S bounds to protein positive amino acids and to non-polar protein regions in a non-
covalent form.  The membrane was hydrated with Tris-buffered saline solution (TBS) during 10 
min with agitation and, then, ponceau staining solution was applied during 5 min with agitation. 
After this incubation, the solution was removed and the membrane was washed with deionized 
H2O to remove the excess of ponceau solution.  
For immunodetection, after total Ponceau removal, membranes were blocked in 5% non-
fat dry milk in 1x TBS-T (0.5% Tween-20), at RT during 4 hours, to reduce non-specific binding of 
antibodies. Following, membranes were incubated with primary antibodies mouse anti-TSG101 
(1:1000) (612697; BD transduction laboratories), raised against TSG101 amino acids 229-319, and 
polyclonal antibody rabbit anti-Calnexin (1:200) (SPA-860; StressGene), used to detect the C-
terminal conserved region of calnexin. Primary antibodies for TSG101 and calnexin were 
incubated for 4h and overnight, respectively. Indirect detection was performed with secondary 
antibodies Amersham ECL Mouse IgG, HRP-linked (1:10000; GE Healthcare Life Sciences) and 
Amersham ECL Rabbit IgG, HRP-linked (1:5000; GE Healthcare Life Sciences). These were 
incubated during 2h, with agitation and at RT. Between primary and secondary antibody 
incubation and after secondary antibody, membranes were four times washed with 1x TBS-T 
(0.5% Tween-20). Protein bands were detected using the chemiluminescence reagent Amersham 
ECL Select Western Blotting Detection Reagent (GE Healthcare Life Sciences) and autoradiography 
Amersham Hyperfilm ECL (GE Healthcare Life Sciences). Enhanced chemiluminescence (ECL) 
reagent is based in luminol substrate oxidation by HRP, generating chemiluminescence at 425 nm. 
The emitted light is directly proportional to the amount of protein. 
 
Statistical analysis 
Statistical analysis was carried out with two-tailed Student’s t-test for assess differences 
between each exosome isolation. Only p-values less or equal to 0.05 were considered significant. 
In graphs, error bars represent standard deviation of three independent experiments. Analysis 
were performed using GraphPad Prism 7 (GraphPad Software, La Jolla, California, USA). 
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2.2.    Results 
 
Exosomes size analysis and zeta potential 
Exosomes were isolated from different body fluids (serum, plasma and CSF) using three 
commercial kits, two precipitation-based reagents (TEI and ExoQ) and one colum-based kit (ExoS). 
After exosomal isolations samples were characterized using different methods. 
Zetasizer Nano ZS based on DLS was used to assess the size of exosomes isolated from 
serum, plasma and CSF, using TEI, ExoQ and ExoS. All kits resulted in nanoparticle isolation within 
the expected size range of exosomes (30-150 nm) and samples had in general a good 
polydispersity index (between 0.08 and 0.70) (PDI) which indicates that nanoparticle populations 
are highly homogeneous (Figure 10 and Table 3). 
 
 
Figure 10. Size distribution of exosome samples derived from serum (A), plasma (B) and CSF (C) obtained through Zetasizer analysis. Each curve represents the average of at least 3 independent sample measurements for each corresponding exosome isolation method. 
  
Considering serum exosome isolations, ExoS shown a homogenous population of vesicles 
with an average peak at 114.31±43.81 nm (only around 8% of vesicles exhibited a larger size than 
exosomes). Exosomes isolated with ExoQ and TEI also presented a greater intensity peek within 
exosome size range, 138.73±37.23 and 117.02±26.86 nm, respectively (Figure 10A and Table 3). In 
both cases an additional peak outside exosome size range was observed for about 18% of 
exosomes isolated with TEI and 31% of exosomes isolated with ExoQ. The existence of peaks that 
do not fit into exosome size range can be explained by nanoparticles aggregation but also due to 
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the fact that DLS analysis can show larger nanoparticle sizes as it measures hydrodynamic 
diameter of particles in movement. TEM analysis did not identified vesicles of larger proportions 
for any of the exosome preparations (Figure 11). In addition, all kits showed modes for diameters 
near 100 nm (Table 3). Plasma nanoparticles isolated with ExoQ and ExoS shown homogeneous 
populations with mean peaks of 138.73±37.23 and 114.31±43.81 nm, respectively, with 21% and 
16% of particles, broadly distributed. Similar to serum, TEI zetasizer analysis revealed two peaks, 
as expected a greater one with nanoparticles within the diameter of 112.91±23.37 nm (12.8% of 
nanoparticles with larger diameters) (Figure 10B and Table 3). Modes of the nanoparticle size 
isolated from plasma with kits were around 105.7 nm for all. Nanoparticle isolated from CSF with 
the three kits were smaller than nanoparticles isolated from plasma and serum, although 
diameter peaks were unique and the exosome range as the corresponding modes; only about 1% 
of vesicles were outside the range for vesicles isolated with ExoS (Figure 10C and Table 3). It is 
important to refer that exosomes isolated from CSF with ExoS had a PDI of 0.82, which indicates a 
broad distribution of nanoparticles sizes (heterogenous population). No significant differences 
(p≤0.05) were found between particle diameter mean peaks of the various kits, for exosome 
preparations from serum and plasma, although differences could be detected for exosomes 
isolated from CSF. Moreover, TEM analysis (Figure 11) revealed spherical vesicles, with the 
expected exosome morphology and sizes, although for all samples microvesicles of smaller size 
than exosomes could also be observed.  
Table 3. Complete characterization of exosome size distribution of exosomes isolated from serum, plasma and CSF. PDI: polydispersity index. 
 Exosome isolation method 
TEI ExoQ ExoS 
Ser
um
 Peak 1 (nm)±SD 117,02±26,86 138,73±37,23 114,31±43,81 Peak 2 (nm)±SD 540,80±270,90 408,59±209,37 - 
Mode (nm) 105,70 122,40 91,28 
PDI (±SD) 0,41±0,05 0,27±0,07 0,22±0,09 
Plas
ma 
Peak 1 (nm)±SD 112,91±23,37 138,73±37,23 114,31±43,81 
Peak 2 (nm)±SD 925,38±266,78 - - 
Mode (nm) 105,7 105,7 105,7 
PDI (±SD) 0,36±0,15 0,28±0,03 0,19±0,02 
CSF
 
Peak 1 (nm)±SD 44,15±12,97 72,95±16,90 100,01±33,94 
Peak 2 (nm)±SD - - - 
Mode (nm) 43,82 91,28 105,7 
PDI (±SD) 0,60±0,34 0,67±0,29 0,82±0,31 
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Figure 11. Morphological characterization of exosome samples by TEM negative staining. Scale bars are in scale with 
each corresponding image. 
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 Zeta potentials of all exosome samples are distributed within the range of -6.11 to -20.8 
mV (Figure 12) and the analysis shown that the stability of samples is distinct depending on with 
the exosome isolation method used, either in serum or plasma. In serum, samples isolated with 
ExoQ and TEI were appropriately stable (zeta potential ≤-10 mV) and significant differences were 
found between zeta potentials obtained among TEI and ExoS (p≤0.01) and also between ExoQ and 
ExoS (p≤0.05). Plasma exosomes isolated with ExoQ were properly stable in contrast with the 
other plasma derived-exosomes samples (p≤0.01). All CSF exosome samples had zeta potential 
values bellow or near -10 mV without differences between the three methods (Figure 12).  
 
Figure 12. Zeta potential evaluation of serum, plasma and CSF-derived exosome samples. Each bar represents mean values of zeta potential (n=3) and error bars shows standard deviations. **p≤0.05; ***p≤0.01 
 
Exosome quantification 
The number of particles isolated from serum and plasma were determined by EXOCET 
assay. Significant differences were obtained for the three commercial kits (Figure 13). In serum, 
both ExoS and ExoQ isolated the highest number of particles, significantly about 2.0-fold more 
particles than TEI (p≤0.01 and p≤0.05, respectively). No differences were observed among ExoQ 
and ExoS serum exosome concentration. Following a similar pattern, for plasma, ExoQ and ExoS 
isolated about 2.5-fold more exosomes than TEI (p≤0.01 for both), but the performance of ExoQ 
and ExoS was not significantly different. In the case of CSF this method failed to quantify the 
number of particles, most probably due to decreased exosome concentrations obtained from 1 ml 
of this biofluid. 
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******
 
Figure 13. Quantification of exosomes isolated from serum, plasma and CSF with the various isolation methods, using EXOCET assay. Each bar represents mean number of exosomes isolated (n=3) and error bars shows standard deviations. **p≤0.05; ***p≤0.01 
 
Protein concentration in exosome samples 
The amount of protein concentration in exosome preparations was measured using BCA. 
For serum derived-exosomes, ExoQ was the kit that gives to the highest protein concentration 
although no significant differences were observed among kits (Figure 14). In plasma exosome 
samples, the three kits exhibited significant differences amounts of protein. ExoQ was the kit with 
best performance, isolating about more 1.3-fold proteins than TEI (p≤0.01) and 2.3-fold more 
proteins than ExoS (p≤0.01). Consistent with EXOCET results, the total protein concentration from 
CSF exosomal samples was unable to be detected using this method. 
*** ***
**
 
Figure 14. Protein concentration analysis of exosome samples. Protein concentration was determined using BCA. Each bar represents mean values of total protein concentration (n=3) and error bars shows standard deviations. **p≤0.05; ***p≤0.01 
 46  
 
To address sample purity, the number of particles isolated from serum and plasma was 
normalized to protein concentration obtained by BCA assay (Figure 15). The total CSF was not 
considered due to protein concentrations near zero. Results obtained were different for serum 
and plasma preparations. In serum-derived exosomes, ExoS had the highest ratio between the 
number of exosomes isolated and total the protein concentration, 2.5-fold higher comparatively 
to TEI (p≤0.01) and 1.3-fold higher than ExoQ, while ExoQ ratio was 1.9-fold higher than TEI 
(p≤0.01). ExoS higher ratios were highlighted in plasma-derived exosome samples; about 4-fold 
higher than TEI (p≤0.01) and 2-fold higher than ExoQ (p≤0.01). Data suggests that ExoS is the 
purest method. 
*** ***
*********
 
Figure 15. Normalization of particle numbers per protein concentration measured by BCA assay. Each bar represents mean values (n=3) and error bars shows standard deviations. ***p≤0.01 
 
Western blot 
Western blot analysis aimed to validate the nature of exosomal samples and to find 
possible differences in performances of the different methods used for exosome isolation. 
Analysis revealed the presence of exosome marker TSG101 and the absence of Calnexin (Figure 
16), the later discards cell contamination of exosomal samples as it was expected. Similar 
enriched levels of TSG101 marker was observed in exosome samples isolated with precipitation-
based reagents (TEI and ExoQ), comparatively to ExoS. 
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Figure 16. Western blot analysis for TSG101 and calnexin in serum, plasma and CSF exosome samples isolated with the three commercial kits. SH-SY5Y cell lysates were used as a control sample. 
 
 Chapter 3. sAPP as potential exosomal diagnostic biomarker for AD 
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3.1.    Materials and methods 
 
Participants and sample collection 
 Samples used in this study were from individuals enrolled in a primary care based cohort 
(pcb-cohort) from the Aveiro region, described in [242]. All volunteers provided written informed 
consent for the cohort study. The study was approved by Ethics Committee for Health of the 
Central Regional Administration of Coimbra (CES da ARS Centro, protocol No. 012804-04.04.2012) 
and by the National Committee for Data Protection (Authorization Nº 369/2012). Serum samples 
were collected in EDTA tubes, centrifuged at 2000g during 15 min, aliquoted and immediately 
frozen at -80ºC. The study group included thirty-two patients (n=32) with Clinical Dementia Rating 
(CDR) scores ≥ 1 and thirty-two sex-age matched healthy individuals (n=32) controls. CDR scale 
evaluates the cognitive and functional performance through six domains: memory, orientation, 
judgment and problem solving, community affairs, home, hobbies and personal care [243]. These 
domains were assessed by an interview in primary care units [242]. Scale is classified as following: 
normal=0, mild dementia=1, moderate dementia=2 and severe dementia=3. From the study 
group, 7 individuals were clinical diagnosed as AD patients. Table 4 show the characteristics (age, 
gender, and CDR scale) of individuals with cognitive deficits and controls enroled in the study. 
Individuals with cognitive deficits have mean (±SD) ages not significantly different from age-sex 
matched controls. 
 
Table 4. Characteristics of individuals with cognitive deficits and healthy controls. 
 Cases  Controls 
CDR scale Nº of individuals Gender (M/F) Ages (mean)±SD CDR scale Number of individuals Gender (M/F) Age (mean) ±SD 
CDR= 1 (Mild dementia) 
10 4/6 70.60±11.06 CDR=0 10 4/6 70.50±10.89 
CDR=2 (Moderate dementia) 
10 4/6 80.40±6.88 CDR=0 10 4/6 80.40±6.31 
CDR=3 (Severe dementia) 
5 1/4 84.60±5.59 CDR=0 5 1/4 83.00±4.18 
AD cases 7 1/6 77.54±4.89 CDR=0 7 1/6 77.14±4.67  
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Exosome isolations from serum 
Exosomes were isolated from cases, age and sex-matched controls using the 
precipitation-based reagent ExoQuick Serum Exosome Precipitation Solution (System Biosciences) 
(ExoQ) according to manufacturer’s instructions with minor modifications. Exosome purification 
was carried out from a starting volume of 250 μl of serum. Samples were centrifuged at 3000g for 
15 min at 4ºC, 200 μl of resulting supernatant were mixed with 50 μl of ExoQ solution and 
incubated at 4ºC during 30 min. Supernatant was discarded, samples centrifuged again at 1500g 
for 5 min and exosome pellet ressuspended in 200 μl of RIPA buffer (Sigma-Aldrich) plus protein 
inhibitors (Roche). To ensure sample for all subsequently procedure, exosome isolations from 
each sample were carried out in triplicated, pooled and frozen at -20ºC. 
 
sAPPα and sAPPβ ELISA assay using serum and serum-derived exosomes 
 The sAPPα levels were monitored using Human sAPPα ELISA Assay (IBL; 27734) and 
Human sAPPβ wild type ELISA Assay (IBL; 27732). Both kits are direct sandwich solid phase ELISA. 
ELISA assays are powerful quantitative immunoassays to detect and quantify a specific protein in 
a mixture. ELISA assays are very sensitive, in this particular case can detect low amounts of sAPPα 
as 0.78 to 50 ng/mL.  
The first step of direct sandwich solid phase ELISA is based on the passively attachment of 
antibodies to a solid phase and antigen capture by coated antibodies. Washes performed after 
this step aim to remove unbounded antigens and then conjugated antibodies specific to antigen 
and labelled with enzymes are added and allowed to incubate for a period of time. Then, next 
washes were again performed, this time to remove the unbounded conjugated antibodies. 
Further, the chromogen/substrate is added and enzymatic catalysis results in colour 
development. This reaction is stopped within some minutes by adding a stop solution that usually 
changes the pH. The final colour is then quantified at appropriate wavelength, in this case at 450 
nm. 
Serum or serum-derived exosome samples from 32 individuals with CDR≥1 and respective 
controls were tested for sAPPα and sAPPβ. The assay was performed from a starting volume of 
100 μl of serum or serum-derived exosome sample (isolated as described above). The standard 
samples were prepared out according to manufacturer instructions, performing serial dilutions. 
About 100 μl of diluted standard, serum or exosome sample could adsorb overnight at 4ºC, in 
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appropriate pre-coated wells with a specific antibody to sAPPα or sAPPβ. Following incubation, 
each well was washed at least 7 times with the 100 μl of recommended wash buffer before the 
addition of Horseradish Peroxidase conjugated Anti-human APP (R101A4) Mouse IgG MoAb Fab’. 
The antibody (100 μl per well) was incubated 30 minutes at 4ºC and then plate was washed at 
least 9 times with 100 μl of buffer. Further, 100 μl of chromogen solution containing the 
horseradish peroxidase (HRP) substrate TMB (3,3',5,5,-tetramethylbenzidine) was added, and 
plate incubated during 30 min and at RT, in the dark. In the presence of HRP enzyme, the 
substrate TMB is converted to a blue colour. The reaction is stopped by the addition of a solution 
of sulfuric acid (in this case 100 μl per well), leading to colour change to yellow and stabilization 
for further read of absorbance at 450 nm. Standard curve was prepared according to datasheet 
instructions with plotting of ELISA standard absorbance against sAPPα or sAPPβ concentrations to 
determine the concentration of sAPPα or sAPPβ of each serum or exosome sample. A blank 
sample of RIPA buffer with protease cocktail inhibitors of 100 μl was used as control to test if the 
buffer interfere with the procedure. 
 
EXOCET assay  
The enzymatic colorimetric EXOCET assay was performed to determine the number of 
exosomes in serum-derived exosome preparations from all individuals in the study group. A 
starting volume of 10 µl of each exosome sample in RIPA buffer was diluted with 90 µl of lysis 
buffer. The mixture was incubated at 37ºC for 5 min for exosome lysis, vortexed and centrifuged 
at 1500g during 5 min to remove general debris. Further, 50 µl of the test sample previously 
prepared was mixed with 50 µl of reaction buffer and added to each well. After 20 min of 
incubation at RT the absorbance of plate was read at 405 nm. The standard curve was created by 
plotting absorbance by number of exosomes, as described by manufacturer. 
 
NCAM1 ELISA assay 
 The NCAM1 (CD56) ELISA assay (abcam; ab119587) was used as a neuronal exosome 
marker. NCAM is a neural cell adhesion molecule is expressed mainly at cell membrane of 
neurons and is involved in neuronal adhesion, neurite outgrowth and synaptic plasticity. This 
protein was also identified in neuronal exosomes. This direct sandwich ELISA assay was performed 
for all serum-derived exosomal samples from the study group. A starting volume of 100 μl was 
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used for test samples and standards (serial dilutions) and could adsorb in the precoated plate 
during 90 min at 37ºC, with a specific goat polyclonal antibody for NCAM. An anti-Human NCAM1 
biotinylated polyclonal antibody from goat was added to each well, incubated during 60 min at 
37ºC. Plate was washed 3 times with TBS too remove unbound antibodies. Next, 100 μl of avidin 
was added and incubated during 30 min at 37ºC. After five washes with TBS, 90 μl of TMB 
substrate was added and incubated during 25 min at 37ºC, producing a blue colour. An acid 
solution was added to stop TMB catalysis reaction and absorbance was read at 450 nm. The 
standard curve was created by plotting absorbance by NCAM protein concentration. 
 
Statistical analysis 
Statistical analysis was carried out using Wilcoxon signed-rank test to assess differences 
between individuals with cognitive deficits and age-sex matched controls in terms of sAPPα, 
sAPPβ and NCAM protein concentrations for serum and serum-derived exosome samples. A ratio 
sAPPα/ NCAM or sAPPβ/ NCAM was performed to normalize samples for exosome neuronal 
nature. Differences between the exosome number of individuals with cognitive deficit and 
controls were assessed using a two-tailed t-test. P-values less or equal to 0.10 were considered as 
significant. Receiver Operating Characteristic curves were carried out to determine the 
performance of the models for discriminating the group of moderate, severe dementia and 
confirmed AD cases from sex and age matched controls. All analysis were performed using 
GraphPad Prism 7 (GraphPad Software, La Jolla, California, USA).  
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3.2.    Results 
 
sAPPα and sAPPβ in serum 
  sAPPα and sAPPβ concentration levels in serum were assessed in two groups, the mild 
cognitive impairment (MCI) patients (CDR=1) and “putative and AD” (PAD) patients (CDR≥1). The 
last group include individuals with moderate to severe cognitive impairment and seven AD clinical 
confirmed cases. Respective mean protein concentrations obtained for sAPPα and sAPPβ can be 
found in the next table: 
Table 5. Mean concentrations of sAPPα and sAPPβ in serum. 
Groups sAPPα mean (±SD) sAPPβ mean (±SD) 
MCI 41.01±9.85 5.62±5.4 
Control group 34.72±11.61 6.40±4.32 
PAD 34.71±10.99 5.03±5.24 
Control group 33.43±8.61 5.24±3.43 
 
 The mean concentrations of sAPPα and sAPPβ in serum were not significantly different 
from respective controls (Table 5 and Figures 17 and 18). A small tendency for higher sAPPα 
means for individuals with cognitive deficits were observed for the two groups, although more 
accentuated in the MCI groups. 
 
Figure 17. sAPPα levels in dementia. sAPPα levels in serum of MCI patients (A) and “putative and AD” cases (B). A graph was also raised for AD confirmed cases that were included in PAD group (C). The horizontal line represents the mean for each set. MCI: Mild cognitive impairment; PAD: “Putative and AD” cases. 
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Contrarily, sAPPβ mean levels exihibited an opposite tendency with lower values in the 
patients groups. However, if we only look at AD cases (Figure 18C) an accentuated decrease of 
sAPPβ mean in AD set when compared to controls could be observed. Noticeably, if the AD outlier 
(Figure 18C, red circle) and respective control were removed (Figure 18C, blue circle), this 
decrease tendency was significant for AD group (2.03±0.81) versus control group (5.01±3.33) 
(p≤0.10).  
 
 
Figure 18. sAPPβ levels in dementia. sAPPβ levels in serum of MCI patients (A) and “putative and AD” cases (B). A graph was also raised for AD confirmed cases that were included in PAD group (C). The horizontal line represents the mean for each set. Red circle indicates exclusion of an AD patient and blue circle indicate exclusion of respective control, for the mean values calculation. MCI: Mild cognitive impairment; PAD: “Putative and AD”. 
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sAPPα and sAPPβ levels in serum-derived exosomes 
 The levels of sAPPα and sAPPβ were also evaluated in exosomes. Exosomes may 
represent a contained source of biomarkers and thus we want to address if sAPPα and sAPPβ 
differences were more marked in these preparations. Mean protein concentrations for the two 
groups are indicated in Table 6. 
Table 6. Mean concentrations of sAPPα and sAPPβ in serum-derived exosomes. 
Groups Exosome sAPPα mean (±SD) 
Exosome sAPPβ 
mean (±SD) 
MCI 31.96±12.85 5.39±3.81 
Control group 30.95±8.93 4.05±2.14 
PAD 25.43±9.08 3.75±2.36 
Control group 26.43±5.75 4.38±2.01 
 
As for serum, no significant differences could be observed in exosomal sAPPα and sAPPβ 
mean levels for MCI and PAD groups (Figures 19 and 20). Only a small decrease in sAPP 
concentrations for “putative and AD” cases and AD group could be detected when compared to 
controls, in particular for sAPPβ. 
 
Figure 19. Exosomal sAPPα levels in dementia. sAPPα levels in serum exosomes of MCI patients (A), “putative and AD” cases (B). A graph was also raised for AD confirmed cases that were included in PAD group (C). The horizontal line represents the mean for each set. Red circle indicates exclusion of an AD patient and blue circle indicate exclusion of respective control, for the mean values calculation. MCI: Mild cognitive impairment; PAD: “Putative and AD”. 
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Figure 20. Exosomal sAPPβ levels in dementia. sAPPβ levels in serum exosomes of MCI patients (A), “putative and AD” cases (B). A graph was also raised for AD confirmed cases that were included in PAD group (C). The horizontal line represents the mean for each set. In A, red circle represents the removal of a mild individual outlier and the blue circle represents the removal of its respective control, for the mean values calculation. In C, red circle indicates exclusion of an AD patient and blue circle indicate exclusion of respective control, for the mean values calculation. MCI: Mild cognitive impairment; PAD: “Putative and AD”. 
 
A more detailed look at AD cases (Figures 19 and 20) did not render in significant 
differences. However, after removal of the AD outlier for sAPPα and sAPPβ (Figures 19C and 20C, 
red circle) and respective control (Figures 19C and 20C, blue circle), sAPPα and sAPPβ 
concentrations were significantly reduced (21.09±6.40 and 2.17±1.62, respectively) when 
compared with controls (28.17±3.20 and 5.49±1.03, respectively) (p≤0.10). Of note, the outlier 
removed was the same in all cases.  
Neither mild sAPPα or sAPPβ levels were significantly different between dementia cases 
and controls, even with the removal of a mild outlier in sAPPβ (Figure 20A, red circle) and 
respective control (Figure 20A, blue circle). 
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Neuronal exosome sAPPα and sAPPβ levels 
 To evaluate if the number of exosomal particles in each preparation was different, the 
EXOCET assay was carried out. No significant differences could be observed for both groups: MCI 
versus controls (1,43x1011±5,57x1010 vs 1,29x1011±5,85x1010) and “putative and AD cases” versus 
controls (1,19x1011±4,55x10 10 vs 1,10x1011±4,22x1010). 
 In order to determine the levels of neuronal derived exosomal sAPP, sAPPα and sAPPβ 
concentrations were normalized for NCAM protein concentrations. Mean concentrations of 
sAPPα and sAPPβ after normalization for NCAM can be found in Table 7. 
Table 7. Mean concentrations of sAPPα and sAPPβ/NCAM ratio in serum-derived exosomes. 
Groups Exosome sAPPα mean (±SD) 
Exosome sAPPβ 
mean (±SD) 
MCI 17.45±7.75 2.96±2.18 
Control group 14.08±3.85 1.81±0.88 
PAD 12.46±5.95 1.78±1.33 
Control group 13.94±4.11 2.28±1.11 
 
 The mean values for sAPPα and sAPPβ ratios were not significantly different from 
respective controls however a small decrease for “putative and AD” cases could be detected 
when compared to controls. Similar results were obtained if we look at AD confirmed cases 
(Figures 21 and 22, respectively). 
 
Figure 21. Neuronal exosomal sAPPα values in dementia. sAPPα levels in neuronal serum exosomes of MCI patients (A), “putative and AD” cases (B). A graph was also raised for AD confirmed cases that were included in PAD group (C). The horizontal line represents the mean for each set. In B, red circle represents the removal of two PAD patients and the blue circle represents the removal of its respective controls, for the mean values calculation. In C, red circle indicates exclusion of an AD patient and blue circle indicate exclusion of respective control, for the mean values calculation. MCI: Mild cognitive impairment; PAD: “Putative and AD”. 
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Figure 22. Neuronal exosomal sAPPβ values in dementia. sAPPβ levels in neuronal serum exosomes of MCI patients (A), “putative and AD” cases (B). A graph was also raised for AD confirmed cases that were included in PAD group (C). The horizontal line represents the mean for each set. Red circle represents the outlier removal of each demented individual from MCI group (A), PAD group (B) and AD cases (C) while blue circles indicates the exclusion of their respective controls. MCI: Mild cognitive impairment; PAD: “Putative and AD”. 
   
 Removal of two outliers from “putative and AD” group and one from AD group and 
respective controls (Figures 21B/C and Figure 22B/C, red and blue circles) results in a significant 
decrease of mean values for both sAPPα and sAPPβ ratios between these groups and the 
respective controls (Figure 23). In both cases, the AD outlier removed was the same. Outlier 
individuals removed exhibit other comorbidities as dyslipidemia, respiratory disease and 
hypertension. However, outliers removal from neuronal sAPPβ MCI cases and respective controls 
(Figure 22A, red and blue circles, respectively) did not resulted in significant distinct means 
between demented individuals and controls. 
                              
Figure 23. Neuronal exosomal sAPP ratios upon outliers removal. *p≤0.10; **p≤0.05 
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Considering the results of Figure 23, receiver operating characteristic curves (ROC) were 
performed for exosome sAPPα and sAPPβ/NCAM ratios, to determine if the profile of these 
neuronal exosomal sAPP was strong enough to distinguish “putative and AD” group from non-
demented control cases. For exosome sAPPα/NCAM ratio the area under the curve (AUC) was 
0.73 (p≤0.05) and for exosome sAPPβ/NCAM ratio it was 0.69 (p≤0.05) (Figure 24). 
 
Figure 24. ROC curves for neuronal exosomal sAPP. sAPPα (A) and sAPPβ/NCAM ratios (B) for discriminating PAD patients from control individuals. 
 
    
Chapter 4. Discussion 
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The research interest in exosomes as a resource for biomarkers linked to disease is  
continuously increasing however still to be stablished is the best method chose among the variety 
of exosome isolation methods, in particular when using biological fluids [233]. Most of literature is 
dedicated to compare ultracentrifugation with exosome precipitation based isolation kits, and 
indeed the benefits of exosome precipitation-based reagents were already shown, particularly in 
terms of exosome and protein yield, time consuming and cost effectiveness for biofluids and cell-
derived exosomes [244, 245]. In this study, it was compared the performance of three commercial 
kits based on exosome precipitation reagents and one column-based method, in different body 
fluids namely serum, plasma and CSF. This comparative study addressed the performance of these 
kits in different body fluids by evaluating the number of particles isolated, the size by TEM and 
zeta sizer analysis, and the nature of the sample, using specific antibodies.  There is a single study 
comparing these three kits for isolation of serum exosomes but does not provide a complete 
characterization [246], another study for serum exosomes comparing ExoQ and TEI [245], and a 
study that uses ExoQ and ExoS for plasma exosomes isolation [247]. Thus, additional studies are 
needed for interlaboratory validation and protocols optimization (e.g. regarding sample volumes 
and methods of exosome characterization). 
In this study, ExoQ, TEI and ExoS were tested for exosome isolation from serum, plasma 
and CSF. Through DLS it was measured the hydrodynamic diameter of nanoparticles, that for all 
kits were within the exosome typical range (30-150 nm), representing the higher percentage of 
particles in the exosomal preparations (Table 3). For serum, using precipitation-based methods 
and for plasma using TEI, a second mean peak between 400-500 nm was identified. Other studies 
had already reported similar results regarding vesicles isolated being outside recommended 
range, with sizes from 300-1000 nm using precipitation-based reagents for serum and plasma 
exosomes [244, 245, 248]. TEM analysis revealed nanovesicles with exosome typical sizes and 
morphology for all exosome samples. All isolated vesicles observed measured less than 150 nm of 
diameter. However, in some preparations, aggregated like-exosome structures were detected 
which can explain the peaks of larger diameter obtained in DLS. In addition, it cannot be excluded 
the fact that DLS measures nanoparticles diameter based in the speed of particles undergoing 
Brownian motion, which is influenced by size, and thus, DLS is more sensitive to the presence of 
higher particles or aggregates. Despite that, the PDI (Table 3) measured for all particles were 
inside the recommended range, between 0.08 to 0.70, except for exosome-derived CSF samples 
isolated with ExoS, showed a polydispersity index of 0.82 which can correlate with the broad 
distribution of sizes obtained by DLS analysis for this sample. PDI superior to 0.7 indicates a very 
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broad range of sizes. Moreover, for all TEM preparations a number of small particles, bellow 30 
nm were evident, these might represent some contamination with high-density, low-density and 
intermediate-density lipoproteins, as previously suggested [249–252]. Other possible 
contaminants are abundant biofluids proteins or even protein aggregates [51, 253, 254]. 
Additional approaches could be used to better clarify the degree of contamination as is the case 
of cryo-electron microscopy that focus on structural details or also immunolabelled TEM [245].  
Zeta potential measures were all negative and most samples had values bellow -10mV, 
the minimum threshold value for what samples with higher zeta potential than this are highly 
subjected to aggregation. Despite the significant differences between some exosome samples, 
thus far there is lack of scientific knowledge to explain these differences and give them a 
biological mean. It was already reported that exosome storage temperature has great impacts on 
exosome stability, recovery and even that storage temperatures above -20ºC for long term 
periods can lead to exosome markers loss as well as morphological changes [255–259]. Exosome 
samples were all properly stored at -20ºC, for similar periods what permit to hypothesize that 
stability differences are not only due to storage conditions. In addition, zeta potential range are 
similar to others previously described for serum- derived exosomes [245, 260]. At our knowledge, 
this is the first study that address zeta potential of plasma and CSF-derived exosomes. 
Further analysis included exosome quantification that was achieved using EXOCET assay, a 
method based in the characteristically enhanced activity of exosome Acetyl-CoA 
Acetylcholinesterase [24, 261]. Exosome quantifications were significantly different among kits. 
For serum and plasma-derived exosomes ExoQ and ExoS isolated about 2-fold and 2.5- fold, 
respectively, more particles in both biofluids than TEI. Indeed, the number of particles isolated 
from serum and plasma was quite similar to Nanosight-based quantifications [262, 263]. The 
number of exosomes isolated from serum were different between TEI and ExoQ (p≤0.01) or TEI 
and ExoS (p≤0.01) in contrast with previous studies that did not observed differences [245, 246]. 
Similar results were obtained for plasma. So, in general terms both ExoQ and ExoS render in 
higher exosomal yields than TEI, for serum and plasma biofluids. Unfortunately, the volume used 
for CSF did not render in a particle number higher enough to be detected by this method. An 
increase of CSF starting volume should be used to enhance exosome isolation using the same kits. 
The total protein quantification was carried out using BCA assay. Regarding protein 
concentration, the precipitation based-reagent ExoQ performed better for serum and plasma-
derived exosomes quantified by BCA assay. It was already reported that the number of exosome 
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particles may not necessarily correlate with protein concentration possibly because exosome 
samples might contain some contaminants that can affect total protein quantification. Therefore, 
the ratio between the number of particles and the concentrations determined by BCA was 
calculated for serum and plasma samples, also in order to give an idea of exosomal sample purity. 
Higher ratios were obtained for the column-based ExoS methods, which highlight the increase 
purity of exosomes isolated by this method. Western blot analysis, confirmed the nature of the 
samples, revealing the presence of exosomal marker TSG101, discarding cells contamination of 
samples with the negative results for calnexin. Taken together data suggest that either TEI or 
ExoQ precipitation-based reagents or ExoS column-based kit successfully isolate exosomes from 
small volume samples of serum and plasma, although at different yields and purity levels. 
However larger amounts of CSF are required to proper CSF-derived exosome isolation. 
 After exosome isolation optimization from biofluids, all conditions were reunited to start 
a pilot study directed to biomarker discovery in dementia and in AD cases. Particular emphasis 
was given to sAPP fragments. sAPP was shown to be a potential biomarker candidate in different 
studies for AD [166, 188, 195]. Currently, AD based molecular diagnostics is carried out in CSF, 
which involves an invasive procedure, thus many studies have focus on the search for more 
peripheral biomarkers. It is reasonable explore for the first time the potential of serum and serum 
exosome levels of sAPPα and sAPPβ. In this study, serum was the biofluid chosen and exosomes 
were isolated from individuals with cognitive deficit and respective controls. 
 No significant differences were found for the mean values of sAPPα and sAPPβ between 
MCI cases and controls, “putative and AD” group, AD cases and respective controls. It was 
observed an opposite tendency between of serum sAPPα and sAPPβ means comparatively to 
controls. While serum sAPPα means tend to increase in individuals with MCI, sAPPβ tend to 
decrease. Despite of not being significant considering all patients, with removal of an AD outlier in 
AD cases led to an significant sAPPβ decrease. Exosome sAPPα and sAPPβ levels follow both the 
same pattern with a small increase of means for mild group compared to control and reduced 
means for “putative and AD” group and AD cases with higher magnitude for sAPPβ. After removal 
of one AD outlier, AD group presented a significant decrease when compared with control 
individuals. The outlier removed was in both cases the same. Upon normalizations for NCAM, 
neuronal sAPPα and sAPPβ patterns are accentuated and a significant decrease in “putative and 
AD” group after removing two outliers could be observed. Significant decrease of sAPPα and 
sAPPβ means is specially accentuated in the case of sAPPα. ROC curves for exosome sAPPα and 
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sAPPβ levels normalized for neuronal nature addresses their potential for discriminate “putative 
and AD” group from controls. Neuronal exosome sAPPα discriminates “putative and AD” cases 
from controls with a modest sensibility of 73% and 69% for neuronal exosome sAPPβ levels. 
A modest number of individuals were used in this study so additional studies, with 
increased number of samples should be carried out to address the real value of sAPP. This pilot 
study aims to prove the potential of these soluble APP forms as candidate biomarkers and not yet 
validate it use as a biomarker. Moreover, instead of normalize sAPPα and sAPPβ exosome levels 
for NCAM it would be interesting to isolate neuronal exosomes and evaluate the potential of 
sAPP, as mentioned with higher number of participants, and ideally perform a multi-centre study. 
 
Final remarks and future perspectives 
 
All precipitation-based and column-based methods compared in this study isolated 
exosomes from serum, plasma and CSF, as demonstrated by TEM visualizations and Zetasizer 
analysis. However, methods had different performances in terms of particle yields, protein 
quantifications and, more importantly, in terms of purity. Precipitation-based methods isolated 
more serum and plasma particles and provided an increased protein yield. For both serum and 
plasma, the greatest purity was achieved with the column based-method.  
For CSF-derived exosomes and although some methods of characterization showed the 
presence of exosomal particles, there is a need to increase the CSF starting volume to enhance 
exosomal yield. In particular, the work carried out in this study facilitates the choice of exosome 
isolation methods and consequently facilitate its’ use for a wide range of downstream analysis 
and in biomarker research. 
Considering the potential of sAPPα and sAPPβ in serum and serum-derived exosomes as 
candidate AD biomarkers, this work showed a decrease of serum-derived neuronal exosome 
means of these soluble forms, in patients scored with moderate to severe cognitive decline 
(CDR≥1). Neuronal exosome sAPPα levels and APPβ levels discriminates “putative and AD” cases 
from controls with a modest sensibility of 73% and 69%, respectively. Further studies are however 
required with a higher number of participants to better assess the discriminatory capacity of 
sAPP. 
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Annexes 
 
Exosome isolation 
- PBS (1x) 
Dissolve 1 pack of BupH Modified Dulbecco's PBS in 500 ml of deionised water. Filter 
solution through a 0.2 μm filter and store at 4 ºC. The final concentration should be 8 mM 
sodium phosphate, 2 mM potassium phosphate, 140 mM NaCl, 10 mM KCl, pH 7.4. 
 
- RIPA buffer (Sigma-aldrich) 
Add 50 μl protease cocktail inhibitors to 950 μl of RIPA buffer. Store at 4ºC. 
 
Transmission electron microscopy (TEM) 
- PBS (1x) 
Dissolve 1 pack of BupH Modified Dulbecco's Phosphate Buffered Saline (Pierce) in 500 ml 
of deionised water. Filter solution through a 0.2 μm filter and store at 4 ºC. The final 
concentration should be 8 mM sodium phosphate, 2 mM potassium phosphate, 140 mM 
NaCl, 10 mM KCl, pH 7.4. 
 
- Paraformaldehyde fixating solution (100 ml): 
Add 4g of paraformaldehyde to 80 ml of filtered H2O. Dissolve by heating the mixture, 
with agitation, at 58ºC. Add one or two drops of 1M NaOH to clarify the solution. Filter 
solution through a 0.2 μm filter, adjust the volume with deionised water and store at 4ºC. 
 
- Phosphotungstic acid hydrate solution (5 ml): 
Add 0.15g of phosphotungstic acid hydrate to 3 ml of sterilized deionised water. Adjust 
pH to 7 by adding 3 or 4 drops of 1M NaOH. Ajust the volume to 5 ml and store at 4ºC. 
 
Protein quantification 
- Working reagent: 
Prepare working reagent considering the proportion 50 reagent A: 1 reagent B. The 
reagent A contains sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1 sodium hydroxide. Reagent B contains 4% cupric azide. 
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SDS-PAGE 
- Lower gel buffer (LGB) (4x) (1L): 
Add 181.65 g of Tris to 900 ml of deionised H2O and mix until complete dissolution. Adjust 
to pH 8.9, adjust the volume to 1L with deionized water and store at 4ºC. 
 
- Upper gel buffer (UGB) (1L): 
Add 75.69 g of Tris to 900 ml of deionised H2O and mix until complete dissolution. Adjust 
to pH 6.8, adjust the volume to 1L with deionized water and store at 4ºC. 
 
- Ammonium Persulfate (APS) 10x (10 ml): 
Dissolve 1g of APS in 10 ml of deionized H2O. Prepare it always fresh before use. 
 
- 10% Sodium docecilsulfate (SDS) (100 ml): 
Dissolve 10g of SDS in 100 ml of deionized H2O. 
 
- Stacking and resolving gel (60 ml): 
Reagents Stacking gel 3.5% Resolving gel 5% Resolving gel 20% 
H2O 13.2 ml 17.4 ml 2.2 ml 
Acrylamide 2.4 ml 5 ml 20 ml 
LGB (4x) - 7.5 ml 7.5 ml 
UGB (5x) 4.0 ml - - 
10% APS 200 μl 150 μl 150 μl 
10% SDS 200 μl - - 
TEMED 20 μl 15 μl 15 μl 
 
- Loading gel buffer (4x) (10 ml): 
To a final volume 10 ml add:  
Reagents V= 10 ml Tris 1M 2.5 ml SDS 0.8 g 
Glicerol 4 ml β-Mercaptoetanol 2 ml Azul bromofenol 1 mg 
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- Tris 1M (250 ml): 
Dissolve 30.3g of Tris in 250 ml of deionized H2O. Adjust pH to 6.8. 
 
- Running buffer (10x) (1L): 
Dissolve 30.3g of Tris (250 mM), 144.2g of glycine (2.5 M) and 10g of SDS (1%) in 
deionized H2O. Adjust pH to 8.3 and adjust the volume to 1L. 
 
Western blotting 
- Transfer buffer (1x) (1L): 
To 700 ml of deionized H2O add 3.03g of Tris (25mM) and 14.41g of Glycine (192mM). Mix 
it until dissolution and the adjust the pH to 8.3. Adjust the volume to 800 ml of deionized 
H2O. Just before use add 200 ml of methanol (20%). 
 
- Tris buffered saline (TBS) (10x) (1L): 
To 700 ml of deionized H2O add 12.11g of Tris (10 mM) and 87.66g of NaCl (150 mM). 
Adjust the pH to 8.0 and the volume to 1L with deionized H2O. 
 
- Tris buffered saline + Tween (TBS-T) (10x) (1L): 
Add 12.11g of Tris (10 mM), 87.66g of NaCl (150 Mm) and 5 ml of Tween 20 (0.05%) of 
deionized H2O. Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionized 
H2O. 
 
- Blocking solution (5%) (100 ml): 
Dissolve 5g of non-fat dry milk in 100 ml of 1x TBS-T. 
 
- Antibody solution (3%) (25 ml): 
Dissolve 0.75g of non-fat dry milk in 25 ml of 1x TBS-T. Add antibody according to 
pretended dilution, mix gently (no vortex) and store at -20ºC. 
 
- Ponceau S Staining solution (0.1%) (50 ml): 
Dissolve 1g of Ponceau S in 50 ml acetic acid and adjust the volume to 1L with deionized 
H2O. Store at 4ºC, protected from light. 
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- Membranes stripping solution (500 ml): 
Dissolve 3.76g of Tris-HCl (pH 6.7) and 10g of SDS (2%) in deionized H2O. Add 3.5 ml  of β-mercaptoethanol (100 mM) and adjust the volum 
